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Das Verständnis des Entstehungsmechanismus von Krebs und Stoﬀwechselkrankheiten
ist von großer Wichtigkeit um neue Behandlungen für diese Krankheiten zu entwick-
eln. Unter den verschiedenen Signalwegen, welche in diesen Krankheiten involviert sind,
spielt Insulinsignalisierung eine bedeutende Rolle in der Modulierung von Zellwachs-
tum und der Stoﬀwechselrate. Die bisherigen Forschungsergebnisse unseres Labors [1]
zeigen dass die Drosophila PP2A regulatorische Untereinheit B′ ein negativer Regulator
von S6K ist; eine bedeutende downstream Komponente der Insulin und mTOR Reg-
ulierung. Um die Funktion dieser regulatorischen Untereinheit und ihrer Auswirkung
auf Translationale Medizin besser zu verstehen, werden Mausmodelle und Zellkul-
turen zur Charakterisierung der Funktion von Säugetier Homolog PPP2R5C in Mäusen
verwendet–welches sich als molekular Checkpoint zur Regulierung der Balance zwischen
Glukose und Lipid Homöostase in Mausleber erwies. Knockdown von PPP2R5C in
Hepa 1-6 und Primären Maus-Hepatozyten zeigt dass PPP2R5C ein negativer Regula-
tor für Triglyceridespeicherung und Glykolyse sein könnte. Knockdown von PPP2R5C
in mehreren Maus Zelllinien resultiert in erhöhter Glukoseaufnahme und Glykolyserate.
Knockdown von PPP2R5C, insbesondere in Mausleber, verändert den Maus Metabolis-
mus auf dramatische Weise. Leber Triglycerid und Glykogen werden gesteigert und
Leber Cholesterin vermindert. Trotz keiner Veränderung im Blutglukosespiegel haben
die Knockdown Mäuse besser Insulinsensitivität und Glukosetoleranz. Zwischen fas-
ten und füttern haben die Knockdown Mäuse auch erhöhte VLDL Aussonderungen der
Leber. Microarray und qPCR Analyse zeigt auch dass mehrere Gene; die in Glykol-
yse und Lipogenese involviert sind, nach PPP2R5C Knockdown hochgeregelt werden.
Den meisten dieser Gene könnte eine Steigerung von HIF1a und SREBP-1 Aktivität
zugeschrieben werden. PPP2R5C Substrat-Trapping identifiziert mehrere Hauptregula-
toren des Stoﬀwechselvorgangs, wie etwa AMPK, HIF1a und STAT3. In vitro Knock-
down von PPP2R5C zeigt auch erhöhte AMPK Aktivität und erhöhte HIF1a Phospho-
rylierung auf. Interessanterweise ist Maus PPP2R5C in db/db Mausleber hochgeregelt,
welches ein Mausmodell von Typ 2 Diabetes ist. Des Weiteren ist menschliche PPP2R5C




Understanding the mechanism of how cancer and metabolic disorders arise is important
for finding new treatments for these diseases. Among diﬀerent signaling pathways in-
volved in these diseases, the insulin signaling holds a special role in modulating the cell
growth and metabolic rate. Our lab’s previous finding [1] showed that the Drosophila
PP2A regulatory subunit B′ is a negative regulator of S6K, a major downstream com-
ponent in the insulin and mTOR signaling. In order to understand better the func-
tion of this regulatory subunit and its implication in translational medicine, the mouse
model and cell culture are employed to characterize the function of its mammalian ho-
molog PPP2R5C in mouse, which is found to be the molecular checkpoint regulating
the balance between glucose and lipid homeostasis in the mouse liver. Knockdown of
PPP2R5C in the Hepa 1-6 cells and mouse primary hepatocytes shows that PPP2R5C
could be a negative regulator for the triglyceride storage and glycolysis. Knocking down
of PPP2R5C in several mouse cell lines results in the increased glucose uptake and
glycolysis rate. Knockdown of PPP2R5C specifically in the mouse liver changes the
mouse metabolism dramatically. The liver triglyceride and glycogen are increased while
the liver cholesterol is decreased. Despite no change in the blood glucose level, the
knockdown mice have better insulin sensitivity and glucose tolerance. During fasting
and refed, the knockdown mice also have increased VLDL secretion from the liver. The
microarray and qPCR analysis on these samples also reveal multiple genes involved in
the glycolysis and lipogenesis are up-regulated upon PPP2R5C knockdown, and most
of these genes could be attributed to the increase in HIF1a and SREBP-1 activity. The
substrate trapping for PPP2R5C identifies several master regulators in the metabolic
process, such as AMPK, HIF1a and STAT3. in vitro knockdown of PPP2R5C also
shows increased AMPK activity and HIF1a phosphorylation. Interestingly, the mouse
PPP2R5C is up-regulated in the db/db mouse liver, which is a mouse model of type
2 diabetes. In addition, the human PPP2R5C is also elevated in the liver from type
2 diabetic patients. This study provides the new knowledge in PPP2R5C’s metabolic
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1. Background
In this thesis project, I have studied the metabolic function of mouse PPP2R5C, which is
a homolog gene for Drosophila PP2A-B′ characterized in our lab [1]. PP2A is a trimeric
protein phosphatase composed of A, B and C subunits. Most of these subunits have
been found to be tumor suppressors [2, 3, 4, 5]. Actually, one of the major functions of
tumor suppressors was found to be reprogramming metabolism to cope with the biomass
accumulation during rapid tumor growth [6, 7, 8]. In the mouse and cellular models I
have studied, I have found mouse PPP2R5C, as a tumor suppressor [9, 10, 11], is an
interesting modulator for balancing the liver glucose and lipid homeostasis. Thus, I will
first introduce background information on cancer metabolism and liver metabolism, then
a detailed discussion of PP2A biology and why I am interested in PPP2R5C specifically.
1.1. Cancer metabolism
Compared with normal, diﬀerentiated, quiescent cells, proliferative tumor cells exhibit
distinct metabolic profile, involving the generation of energy from aerobic glycolysis, a
phenomenon called "Warburg Eﬀect" initially described by Otto Warburg at last century
[12, 13, 14]. In proliferative tissues or tumors, quickly dividing cells ferment a major
fraction of glucose into secreted lactate and ineﬃciently produce ATP from glycolysis
(2 ATP molecules per glucose) instead of the mitochondrial oxidative phosphorylation
in mitochondria (~36 ATP molecules per glucose).
The preference over fermentation in glucose utilization was first discovered in yeast
[7]. Otto Warburg’s findings in proliferative ascites tumor cells established the glucose
utilization into lactate secretion, even under hyperoxia condition. Warburg and his
contemporaries postulated that the aerobic glycolysis is the specific marker for cancer
cells, and defective mitochondria are responsible for the energy production switch to
glycolysis. The "Warburg Eﬀect" is generally true for the majority of cancer cells, and
extensively applied in the clinical diagnosis for tumor detection in human by the 18F-
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deoxyglucose positron emission tomography (FDG-PET) [7].
Besides extensive clinical applications of the Warburg eﬀect, recent studies in cancer
cells showed that most of the cancer cells are not defective in mitochondrial function,
including the oxidative phosphorylation for eﬃcient ATP generation [15, 16, 17]. These
observations suggest the existence of an alternative explanation for the ATP produc-
tion switch from oxidative phosphorylation to aerobic glycolysis, which is the altered
metabolism in cancer cells for supporting anabolic growth requirements in the prolifer-
ation, including fast ATP generation, massive biosynthesis of macromolecules and tight
maintenance of the cellular redox status [8]. It is now clear that the metabolism change
in the cancer cells is driven by the growth factor signaling transduction, and not the
secondary indirect consequences upon the increasing demand from fast growth and di-
viding, but rather tightly regulated metabolism reprogramming to increase the nutrient
uptake and flux under the control of activated oncogenes or inactivated tumor suppres-
sors [7]. This new understanding of cancer metabolism has become one of the hallmarks
of cancer [6].
1.1.1. Metabolism switch in quiescent vs proliferative cell
Most of the non-proliferative cells in diﬀerentiated tissues are quiescent and producing
ATP eﬃciently via the oxidative phosphorylation in mitochondria. In the presence
of oxygen, these cells preferentially generate ATP from oxidation of glucose into CO2
by oxidizing glycolytic product pyruvate in the TCA cycle happening in mitochondria.
Besides a net gain of 2 ATP generated from the glycolysis, NADH, GTP and FADH2 are
produced during sequential oxidation of the pyruvate in the TCA cycle. These products
from the TCA cycle are fueling the oxidative phosphorylation complexes I-V to generate
~36 ATP/glucose in total. Under anaerobic conditions, diﬀerentiated cells could produce
a large amount of lactate from glycolysis while the oxidative phosphorylation is bypassed.
In contrast, cancer cells utilize 10% glucose for the biosynthetic pathway upstream of
pyruvate production and the rest 90% glucose for pyruvate production [7, 18]. Among
this 90% glucose, 5% of them will be metabolized via oxidative phosphorylation and
the rest 85% of them will be converted to lactate. This process could only generate ~4
ATP/glucose (Figure 1.1). One of the possible reasons for employing this low-eﬃciency
ATP production by cancer cells is that the nutrient availability is not an issue for
them. Cancer cells live in an environment having continuous supply of glucose and
other nutrients. There are evidences that the ATP production is never a limiting factor
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during the cell division [19, 20]. Even highly stimulated to growth and dividing, cancer
cells are still able to maintain high ATP/ADP and NADH/NAD+ ratios.
Figure 1.1.: Glucose metabolism in cancer cells. Modified based on Vander Heiden et al. [18].
Beyond the ATP requirement, cancer cells also need double their cellular contents for the
cell division. There are huge needs for nucleotides, amino acids, and lipids for the macro-
molecular biosynthesis and new membrane formation. Although ATP is indispensable
for most of the biomass accumulation reactions, other intermediate metabolites are also
needed. For example, the palmitate synthesis for reconstituting new cellular membrane,
requires 8 molecules of acetyl-CoA as the carbon source, 14 molecules of NADPH for the
reducing power, as well as 7 molecules of ATP. One molecule of glucose could generate
up to 36 ATP, or 30 ATP plus 2 NADPH through phosphate pentose pathway, or just
provide 6 carbons for macromolecular biosynthesis. Now back to the palmitate synthe-
sis, one molecule of glucose could provide ~5 times ATP needed for 16-carbon fatty acid
synthesis, or 1/7 of the NADPH needed for it. There is a 35-fold asymmetry between
the need for ATP and that for NADPH, given that 3 additional glucose for making the
acetyl-CoA as the carbon source for the palmitate synthesis [21]. Thus, during the cell
proliferation, a majority of glucose can not undergo the oxidative phosphorylation to
generate ATP, otherwise the resulting high ratio of ATP/ADP will negatively control
the flux of glycolysis and compromise the production of acetyl-CoA and NADPH, which
leads to the impaired biomass accumulation. The "by-product" lactate could also be
converted into glucose again in the liver by the Cori cycle [21].
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1.1.2. Signaling in metabolism reprogramming
Recently, there were increasing evidences support the hypothesis that the metabolic re-
programming is a hallmark of the tumor development and the primary consequence of
the mutation in oncogenes and tumor suppressor genes [6, 7]. The cancer cell prolifera-
tion not only relies on a large amount of energy consumption, but also needs other build
blocks for the cell growth, such as amino acids for the protein synthesis and fatty acids
for the lipid bilayer formation. For these purposes, the cell metabolism must undergo
a massive reprogramming to fulfill the increased anabolic demand for the cell growth
and division. Interestingly, the cancer cell metabolic reprogramming and metabolic syn-
dromes such as type 2 diabetes and hepatosteatosis (fatty liver), are sharing a broad
range of signaling pathways in etiology. One of these is the Insulin/PI3K/AKT/mTOR
pathway. Activation of PI3K/AKT is probably the most prominent lesion in various
types of cancer. mTOR, a downstream target of PI3K/AKT, is well-characterized for
its role in enhancing the protein synthesis, glycolysis and lipogenesis via the S6K, HIF1a
and SREBP-1 respectively [22, 23, 24]. Dissecting the signaling network behind the in-
sulin signaling could potentially reveal more pharmaceutical targets for treating both
cancers and metabolic syndromes.
1.2. Liver metabolism
The liver is the largest organ in the body, contributing about 2% total body weight
in human and 5% in mouse [25]. The liver is a lobular structure composed of many
cylindrical liver lobules as the basic function unit. Each unit containing 3 types of cell:
hepatocytes, endothelial cells and Kupﬀer cells (local macrophage cells in the liver). The
liver performs many important functions in physiology including: (1) the filtration and
storage of blood (2) the metabolism of carbohydrates, lipids, proteins, hormones and
foreign chemicals (3) the bile acid synthesis (4) the vitamin and iron storage (5) the
synthesis of serum proteins, such as the albumin, coagulation factors [25].
In this thesis project, the liver glucose and lipid metabolism are the main focuses. The
liver is especially essential organ for maintaining the blood glucose level. The liver can
serve as a glucose buﬀer. In the postprandial phase, a large amount of blood glucose
is transported into the liver for the glycogen synthesis and lipid de novo synthesis [26],
which allow the removal of excess blood glucose and returning into the blood when
the glucose level drops below the normal. The liver can also synthesize glucose via
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gluconeogenesis when blood glucose falls below the normal. During this process, a large
amount of amino acids and glycerol released from triglycerides are converted into glucose
and released into circulation to maintain the normal level of blood glucose.
For lipid metabolism, the liver is the major organ for a certain aspect of the fat
metabolism, including: (1) the fat oxidation (2) the synthesis of lipoproteins, cholesterol
and phospholipids (3) the free fatty acid and triglyceride synthesis from carbohydrates
and proteins [25]. The major sites for de novo lipogenesis are the liver and adipose
tissues. In the liver, the products from lipogenesis are either stored as lipid droplets
in the liver or secreted in the form of VLDL (Very Low Density Lipoprotein), which
delivers the endogenous derived lipids to peripheral organs.
1.2.1. Liver glucose regulation
After digestion in the alimentary tract, final products of carbohydrates are glucose,
galactose and fructose. Much of the fructose and all of the galactose are interconverted
into glucose in the liver. Thus, the glucose becomes the dominant carbohydrate circu-
lating in the blood.
In the postprandial phase, the liver plays a critical role in nutrient absorption and
metabolism, since it is the first barrier to filter all ingested nutrients through the hepatic
port vein. This process filters out micro-organisms absorbed together with nutrients,
such as bacteria, fungi, viruses and parasites. As the first access to nutrients, the liver
is exposed to higher nutrient levels than peripheral organs. A large amount of glycogen
is synthesized in the liver in order to relieve the modest hyperglycemia after meal for a
normal individual. In addition, the liver also produces glucose to maintain the glucose
homeostasis during the fasting state. In a diabetic person, the liver is one of the major
culprits for hyperglycemia due to the impaired balance between glucose uptake and
production in the liver [27].
1.2.1.1. Liver glucose uptake
In the postprandial phase or during the high glucose load via oral or enteral delivery, the
liver shifts the balance toward more glucose uptake than endogenous glucose production
(NHGU (Net Hepatic Glucose Uptake) shifts from modest to high in dog [28, 29].).
Glucose uptake experiments in human and dog have shown that the liver NHGU takes up
25–40% of the administered glucose, while muscle and adipose tissues take one-third, and
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the non-insulin-sensitive glucose obligating tissues (brain, red blood cells, etc.) absorb
the remaining one third (Figure 1.2). Actually, the liver NHGU underestimates the role
of the liver in glycemic control. The total capacity of the liver in glucose disposal upon
oral glucose load is about 60–65%, demonstrates the great importance of the liver in the
glucose clearance and production [26]. Once taken up by the liver, glucose is converted
to glucose-6-phosphate by the liver glucokinase (L-GCK). Unlike other hexokinases, the
L-GCK is not inhibited by glucose-6-phosphate. This allows the active glycogen storage
in the postprandial phase.
Figure 1.2.: Glucose absorption among metabolism related tissues. Modified based on Moore et al.
[26].
1.2.1.2. Glycolysis for energy and metabolite intermediate production
Glucose-6-phosphate is further metabolized in glycolysis or stored in the form of glyco-
gen. Glycolysis converts glucose into pyruvate with 2 ATP and 2 NADH released from
one glucose molecule. The pyruvate is further decarboxylated to acetyl-CoA and then
submitted for the TCA cycle or de novo lipogenesis. The pentose phosphate pathway
(PPP) is another way of metabolizing glucose, which generates NADPH as the antioxi-
dant or reducing equivalent for the de novo lipogenesis and cholesterol synthesis.
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1.2.1.3. Glycogen storage and breakdown in the liver
After the glucose is absorbed into the liver, it can be metabolized in glycolytic pathway
to release energy and building blocks for the protein and lipid synthesis, or it can be
stored as glycogen for future use such as releasing glucose in fasting state. The liver
can store as much as 5–8% of its weight as glycogen. The conversion of glucose to
glycogen allows the liver cell store large amount of carbohydrates without increasing the
intracellular osmotic pressure.
The chemical process of glycogen synthesis is that glucose-6-phosphate is interconverted
into glucose-1-phosphate; this is converted to uridine diphosphate glucose, which is fi-
nally synthesized into glycogen by glycogen synthase (GS). The GS can be regulated
by several pathways. The glucose-6-phosphate can allosterically activate GS. The phos-
phorylation of GS can also reduce its activity. Numerous kinases have been shown to
regulate GS via phosphorylation [30]. The phosphorylation of GS occurs both in the
primary and secondary phosphorylation sites. Primary phosphorylation events are initi-
ated by the phosphorylase kinase, PKA, AMPK, PKC, CaMK-II, and CK-II. Secondary
phosphorylation events are initiated by the GSK-3 and CK-I.
In fasting state, the liver produces glucose for the whole body by breaking down glycogen
into glucose in a process called glycogenolysis. This process is catalyzed by the glycogen
phosphorylase. The glycogen phosphorylase is regulated by the allosteric activation of
AMP and activated by the phosphorylation via PKA. The product from glycogenoly-
sis is glucose-1-phosphate, which will be further converted to glucose-6-phosphate by
phosphoglucomutase. And the glucose 6-phosphatase remove the phosphate group from
glucose-6-phosphate to produce glucose which will be transported out of the liver.
1.2.2. Liver lipid metabolism
1.2.2.1. Dietary lipid absorption
During the digestion, triglycerides from the food are split into monoglycerides and fatty
acids, which are re-esterified in the intestinal epithelial cell into triglycerides and re-
leased into the lymphatic system as lipoprotein droplets called chylomicrons (Figure 1.3).
Chylomicrons also contain cholesterol and phospholipids absorbed from the food. The
half-life of chylomicrons is less than 1 hour. Most of the chylomicrons are cleared out in
the capillary of muscle, adipose and liver by the action of the lipoprotein lipase (LPL).
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The remnants of chylomicron are absorbed by the liver via the LDL (Low Density
Lipoprotein) receptor, LDL receptor-related protein (LRP) and scavenger receptor B-1
mediated endocytosis. The engulfed chylomicrons in hepatocytes are digested in the
lysosome to release glycerol, fatty acids, cholesterol, which are recycled into VLDL.
1.2.2.2. Lipoprotein particle for lipid transportation and redistribution
Besides chylomicrons, there are four major types of lipoprotein particles circulating in
the plasma (Figure 1.3). Most of these lipoprotein particles are synthesized by the
liver and employed to redistribute triglycerides, cholesterols, and phospholipids among
peripheral tissues. These lipoprotein particles are classified based on their density mea-
sured in the ultracentrifugation: (1) the VLDL is synthesized in the liver and containing
the highest amount of triglycerides (~70%) and modest amount of cholesterol (~7.5%)
and phospholipids [31]; (2) the IDL (Intermediate Density Lipoprotein) is derived from
the VLDL, in which triglycerides are partially removed; (3) the LDL is derived from
the IDL, in which almost all triglycerides are absorbed by peripheral tissues, left with
very high amount of cholesterol (~45%) [31]; (4) the HDL (High Density Lipoprotein) is
synthesized in the liver or intestine epithelium, containing high concentration of protein
(~50%) and modest amount of cholesterols (~20%) and phospholipids [31]; .
In contrast to the chylomicron for exogenous lipid transportation, the primary function
of the VLDL is transporting endogenous liver-derived triglycerides and cholesterols to
peripheral tissues such as the muscle and adipose tissues. As partially digested lipopro-
tein from VLDL, the IDL is either taken up by the liver or continually circulating in the
plasma to convert into LDL. The LDL contains high amount of cholesterol, which is also
called the "bad cholesterol" in comparison to the "good cholesterol" in HDL. Increasing
blood cholesterol from LDL is a strong risk factor for causing the atherosclerosis. The
HDL is responsible for the delivery of the cholesterol to peripheral tissues and the re-
moval of excess cholesterol from the plasma in a process called the reverse cholesterol
transport [32, 33].
1.2.2.3. de novo lipogenesis in the liver
Whenever a greater amount of the carbohydrate than it can be used immediately such
as in glycolysis or stored in the form of glycogen, the excess is quickly converted to
triglycerides. Most of the triglyceride synthesis occurs in the liver, while a small frac-
tion also occurs in the adipose tissue. The hepatic de novo lipogenesis include the fatty
8
1. Background
Figure 1.3.: The lipid absorption and lipoprotein particle redistribution among metabolism related
tissues.
acid synthesis from the acetyl-CoA and malonyl-CoA, and further synthesis of triglyc-
erides. The fatty acid synthesis is catalyzed by the acetyl-CoA carboxylase for the
malonyl-CoA synthesis and the fatty acid synthase for the fatty acid elongation up to
16 carbons. The fatty acid and its metabolites are the major culprits for lipotoxicity.
Thus, fatty acids are quickly further stored as triglycerides, which are relatively inert
and shown to have a hepatic protective role [34]. The triglyceride synthesis starts from
the glycerol-3-phosphate and fatty acid-CoA by the glycerol-3-phosphate acyltransferase
(GPAT) to form the lysophosphatidic acid, then further adding fatty acids stepwise by
the acylglycerolphosphate acyltransferase (AGPAT), phosphatidic acid phosphohydro-
lase (PAP) and diacylglycerol acyltransferase (DGAT) to have triglycerides. Finally,
triglycerides are packaged into the VLDL.
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1.2.2.4. b-oxidation of fatty acids
The degradation and oxidation of fatty acids occur in mitochondria, peroxisomes and
ER [35]. For the b-oxidation in mitochondria, fatty acids are first transported via the
help from the carrier called carnitine. Then fatty acids in mitochondria are progressively
processed to release the acetyl-CoA and reducing equivalent such as FADH2 and NADH.
The b-oxidation of fatty acid will release a tremendous amount of energy from it. For
example, one molecule of stearic acid will release net gain of 146 molecules of ATP after
complete oxidation [25]. The acetyl-CoA can also be converted to the ketone body in
case of excess fatty acid, or further processed in the TCA cycle. Two acetyl-CoA can
be condensed into one acetoacetic acid. The acetoacetic acid can also be converted
to the b-hydroxybutyric acid [36]. In ER, long-chain fatty acids can be degraded via
the w-oxidation by the cytochrome P450 [37]. PPARa and insulin are the positive and
negative regulator for the fatty acid oxidation [35].
The formation of ketone bodies, which is also called the ketogenesis, is mainly happening
in the liver cell mitochondrial matrix when blood glucose level is low and the liver has
to provide extra energy for other organs, such as the muscle, heart and brain. After its
production in the liver, the water soluble ketone body species are released into the blood,
and transported into other organs where the acetoacetic acid and b-hydroxybutyric acid
can be re-converted into the acetyl-CoA as the energy source.
1.3. PP2A and its biology
The reversible protein phosphorylation is one of the most abundant post-translational
modifications (PTMs), in which the protein residue serine/threonine/tyrosine is phos-
phorylated by kinases and de-phosphorylated by phosphatases. The regulation of pro-
tein phosphorylation is considered to be one of the most common way of the protein
function regulation, which switches protein between the active and inactive form, or
between the stabilization and degradation, or diﬀerent cellular localizations [38, 39, 40].
While the previous basic research and pharmaceutical development is mainly focused
on the kinase activity modulation to aﬀect the protein phosphorylation, it is now also
being recognized that the protein phosphatase could also be an important regulator in
the protein phosphorylation and provide the new drug candidate to change the protein
phosphorylation pharmacologically [41, 42, 43, 44, 45].
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Table 1.1.: PP2A gene superfamily
compositiona.
Subunit Gene Name Protein Name
PP2A-A PPP2R1A PR65aPPP2R1B PR65b






















a Adapted from Perrotti et al. [46].
1.3.1. PP2A structure
The protein phosphatase 2 (PP2A) is a heterotrimeric serine/threonine phosphatase
with broad substrate specificity and diverse cellular functions. The PP2A is composed
of a dimeric core enzyme formed by a scaﬀold A subunit and a catalytic C subunit, and
a regulatory B subunit for expanding PP2A’s substrate specificity. While the A and C
subunit sequence have extraordinary sequence conservation throughout eukaryotes, the
regulatory B subunits show more heterogeneous sequence evolution. This indicates a
highly conserved core enzyme functionality of the PP2A during evolution, but continuous
evolution on the B subunit for expanding substrate specificity constantly.
Multicellular eukaryotes are believed to express four classes of regulatory subunits: B, B′,
B′′, and B′′′ , with at least 17 members in these diﬀerent subfamilies (Table 1.1). Beyond
this layer of complexity in the gene family, each gene can also have various splicing
isoforms. In total, diﬀerent combinations of certain isoform of certain gene subfamily
member provide more than 200 possible variations of the PP2A. This will also explain
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why phosphatases, even less represented than kinases in the genome, can counteract the
phosphorylation events by many kinases. The Table 1.2 shows the unbalanced number
of genes for phosphatases and kinases in diﬀerent genome, from Yeast to Human.
1.3.1.1. PP2A catalytic subunit
Mammalian PP2A catalytic subunit (PP2A-C) is a metallophosphatase, which requires
normally the Mg2+ in its active center for catalytic activity. The PP2A-C subunit is
encoded by two gene subfamily members, a and b, which share 97% amino acid sequence
identity with only minor diﬀerence at the beginning N-terminal. The two sub-members
of PP2A-C are diﬀerentially expressed. The PP2A-Ca is about 10 times more eﬃciently
transcribed than the PP2A-Cb [47], probably due to the higher expression capacity of
the PP2A-Ca promoter [48]. The overexpression of PP2A-C in mammalian cell was not
successful. And the knockout mouse of PP2A-Ca was not viable and die at embryonic
6.5 day [49], which indicated the importance of PP2A-Ca in the mouse development and
its non-redundancy in term of rescuing by PP2A-Cb.
1.3.1.2. PP2A scaﬀold subunit
The scaﬀold A subunit is also encoded by two distinct isoforms, PP2A-Aa and PP2A-
Ab, which share 86% sequence identity. The A subunit is the structural subunit which
provides scaﬀold for the association of regulatory B subunit and catalytic C subunit.
Since the diﬀerent regulatory subunit binds with the same or overlapping surface on the
A subunit, the association of regulatory subunit to the holoenzyme is mutually exclusive
[50, 51]. This structural characteristic in PP2A defines the existence of potential PP2A
sub-pool and diversified substrate specificity. Mice that are homozygous for PP2A-Aa
knockout are embryonic lethal [52]. The oocyte-specific knockout of PP2A-Aa leads to
Table 1.2.: Kinase/phosphatase gene number imbalance in genomea.
Gene Family S. cerevisiae D. melanogaster C. elegans H. sapiens
Total Gene Number 6122 13600 18988 25000
Total Protein Kinase
Number
124 236 493 518
Total Protein Phos-
phatase Number
37 93 185 119 (21 Protein S/T
Phosphatase)
a Adapted from Seshacharyulu et al. [2].
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severe defect in the female meiosis and fertility in mice [53]. The mouse knock-in model
of human cancer-associated mutations in PP2A-Aa increases the lung cancer incidence
and indicates its potential tumor suppressor function [52].
1.3.1.3. PP2A regulatory subunit
Regulatory subunits of PP2A are diverse (Table 1.1) and low in sequence similarity
between these four gene families, even though they all bind to similar repeats in the
A subunit. From the crystal structure, it was postulated that the regulatory subunit,
together with the catalytic subunit, establish the binding groove for substrates [54]. The
diversity of regulatory subunit can partially explain how PP2A counteracts phosphory-
lation from multiple kinases by having diversified substrate recognition.
The PP2A-B gene family has four sub-members (Table 1.1). The PR55a and PR55d are
expressed in almost all tissues, while the PR55b and PR55g are highly expressed in the
brain [55]. Structurally, the PP2A-B family protein’s common feature is the existence
of 5 degenerated WD40 repeats, which are believed to be involved in protein-protein
interactions.
The PP2A-B′ gene family currently contains 5 member (Table 1.1). While the PR61a,
PR61b and PR61e are mainly localized in cytoplasm, the PR61g and PR61d are localized
both in cytoplasm and nucleus. For tissue expression pattern, the PR61a and PR61g
are expressed in almost all tissues, especially high in the heart and skeletal muscle.
And the PR61b and PR61d are highly enriched in the brain [56, 57, 58]. All PP2A-B′
genes share a conserved central region (80% identical), with diﬀerent C and N terminal.
This indicates the central region is probably more involved in the association with the
scaﬀold and catalytic subunit, while the C and N terminal could be involved in regulating
substrate diversity.
Initially, the PR72 and PR130 were discovered as founding members of PP2A-B′′ [59].
The only sequence diﬀerence between them is located at N terminal, which raises the
possibility that PR72 and PR130 are originated from alternative splicing. Two other
member PR48 and PR59 are discovered by the yeast two-hybrid as interaction partners
for the retinoblastoma-related p107 protein and Cdc6 respectively [60, 61].
The PR93 and PR110 are discovered as members of PP2A-B′′′ family based on their
sequence conservation with PP2A-B′ family. These two proteins are all calmodulin-




1.3.2. PP2A in signaling
PP2A is essential to the majority of signaling pathways, including cell cycle control,
Wnt signaling, insulin signaling, apoptosis, cell adhesion and cytoskeleton dynamics,
etc. (Details in Figure 1.4). The mis-regulation of PP2A complex will influence on a lot
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Figure 1.4.: PP2A is involved in many signaling pathways by counteracting phosphorylation events
by many kinases. Adapted from Perrotti et al. [46].
1.3.2.1. PP2A in metabolism
Multiple PP2A regulatory subunits have been demonstrated to be involved in regulating
the metabolism via the Insulin/AKT/mTOR signaling pathways. In Drosophila, Hahn
et al. demonstrated that PP2A regulatory B′ target S6K to modulate the phosphoryla-
tion of its activation site in our lab, and this regulation was conserved even in the Hela
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cell line [1]. Another Drosophila B′ subunit Widerborst modulates activated AKT via
direct interaction and change the lipid droplet size and expression of lipid storage pro-
tein perilipin [63]. The C. elegans B′ subunit pptr-1 could also directly regulate AKT’s
phosphorylation in vivo and impact the life span, fat storage phenotype of worms [64].
In the mammalian system, AKT was also found to be associated with the PP2A–B55
holoenzyme, and its phosphorylation at Thr–308 was compromised by overexpressing
PR55a subunit in both FL5.12 and NIH3T3 cells [65]. In 3T3-L1 adipocytes, over-
expression of small t antigen, which generally inhibits PP2A activity, was found to have
multiple impacts on the insulin pathway, including increased phosphorylation of insulin
signaling downstream eﬀector–AKT and GSK-3b [66]. The inhibition of PP2A by the
small t antigen in 3T3-L1 adipocytes enhanced the glucose uptake both in basal and
insulin-stimulated condition. Another important master regulator in metabolism, the
AMPK, was also found to be negatively regulated by PP2A [67, 68, 69]. In HepG2
cells, heat shock stress will dephosphorylate AMPK and enable to relieve the AMPK-
mediated suppression on HSP70 expression [69]. And the AMPK inhibition after heat
shock stress was shown to be mediated by PP2A. Intracellular calcium or palmitate could
also inactivate AMPK via PP2A. The PP2A-B′′ subunit PR72 is known to have calcium
binding sites, and could potentially be involved in intracellular calcium-mediated AMPK
inhibition [68]. Excess fatty acid treatment, such as palmitate, could also inactivate
AMPK via PP2A [67].
1.3.2.2. PP2A in Wnt signaling
In Xenopus, B′ subunit PR56a was discovered to the negative regulator for the b-
Catenin phosphorylation, which lead to the degradation of b-Catenin via the ubiqui-
tin/proteasome pathway [70]. However, recent evidences showed the PP2A has more
complicated control in Wnt signaling [5]. Before Wnt ligand binding, b-Catenin is lo-
cated in destruction complex including APC, AXIN, and GSK3b. The PP2A B sub-
units, PR61a-d, binds to either APC or AXIN to destabilizing the b-Catenin. However
the mechanism is still not clear. Upon Wnt ligand binding, the Wnt downstream eﬀector
Naked, which causes a negative feedback on Wnt signaling, requires the PR72 for its neg-
ative regulation, and is repressed by the PR130 (alternative splicing form of the PR72).
Additionally, both PR61e and PR55 could enhance Wnt signaling by destabilizing the
inhibitory GSK3b (Figure 1.4).
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1.3.2.3. PP2A in MAPK signaling
For MAPK kinase signaling cascades, PP2A has also both inhibitory and activating
role [5]. Depending on the diﬀerent combination of PP2A complexes, almost all MAPK
pathways can be negatively regulated [71]. Both in vivo and in vitro studies has shown
that inhibition of PP2A increases ERK and MEK phosphorylation [71]. Furthermore,
PR61b and PR61g directly de-phosphorylate ERK [5] (Figure 1.4). PP2A was also
shown to interact with Shc, the upstream regulator in MAPK signaling, and suppress
its tyrosine phosphorylation and activation on MAPK signaling cascade [71].
Related to PP2A’s activating role, PR55a binds and de-phosphorylates KSR1 and RAF
upon RAS activation. And this leads to the plasma membrane recruitment of RAF
and subsequent enhanced binding between RAF and RAS, therefore stronger activation
of MAPK signaling [5]. On the other hand, PR55g interacts with c-SRC and inhibits
c-SRC’s positive regulation on RAF independently from RAS activation.
1.3.2.4. PP2A in apoptosis
PP2A has also pro-apoptotic activity via its inhibitory eﬀect on AKT, which inactivates
the anti-apoptotic protein BCL2 and activates pro-apoptotic factors like BAD and BIM
[5, 72] (Figure 1.4). PP2A directly binds BCL2 and BIM and de-phosphorylates them.
Also, PP2A directly binds to the BH4 domain of BCL2 and removes the phosphorylation
at Ser70 of BCL2, which causes enhanced interaction between p53 and BCL2 to inhibit
BCL2’s anti-apoptotic function. Additionally, the inhibition of PP2A by okadaic acid
or siRNA increases eIF4E phosphorylation via MNK kinase [73]. These findings are
consistent with the tumor suppressor role of PP2A.
1.3.2.5. PP2A in cell cycle control
PP2A has a fundamental role in controlling cell cycle. During G1–S transition, PR56g
is translocated into the nucleus and PP2A terminal methylation levels also change [5].
Also, PR55a is inhibiting CDK1-Cyclin B complex via the inhibition of CAK and Wee1
kinase. PR56d could also de-phosphorylate CDC25 and inactivate it. The PR56 fam-
ily could also regulate sister chromatid cohesion, which is important for proper chro-
mosome segregation in mitosis and meiosis [53, 74]. In my own PhD thesis project,
over-expression of mouse PP56g (PPP2R5C) in Hepa 1-6 has also resulted in dense
chromosome in DAPI staining, which confirmed the B′ subunits’ role in chromosome
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segregation (data not shown).
1.3.2.6. PP2A in cell proliferation
PP2A has been demonstrated with multiple evidences for its tumor suppressor activity
in the human cell transformation [3, 4]. Viral antigen SV40 small T antigen or tumor-
inducing toxins like okadaic acid and microcystin-LR have been shown to be the viral
or chemical inhibitor for PP2A activity [75, 76]. In addition, in vivo inhibitor for PP2A
CIP2A, an endogenous interacting protein for PP2A, has been found to be the stabilizer
for c-Myc and mediating PP2A’s inhibition in human malignancies [42, 77].
PP2A scaﬀold and regulatory subunits have been shown to be mutated or down-
regulated in multiple cancers [2]. Knockdown of PR56g in HEK cell inhibits PP2A
phosphatase activity similar to the extent achieved by SV40 small T antigen and induces
anchorage-independent tumor growth [78]. The PP2A PR56g containing holoenzyme
has tumor growth suppression activity via de-phosphorylation on the p53 at Thr–55 [9,
11], and leads to the growth arrest and inhibition of cell proliferation.
1.4. Aim of study–PPP2R5C
In our lab, homolog of PPP2R5C in Drosophila, PP2A-B′, has been previously shown
that it regulates the organismal metabolism [1] via directly de-phosphorylating S6K1 in
Drosophila. In agreement with S6K activation phenotype, fly with PP2A-B′ whole body
knockout had increased insulin signaling phenotype, which was the decreased life span
and whole body triglyceride. The initial study in Hela cell also shows that the human
homolog of PP2A-B′, PPP2R5C, also negatively regulates the S6K phosphorylation.
The naturally following question would be whether there is any link between PPP2R5C
and metabolic status in more translational related context, such as in mice or human
patients.
The knockout mice in PPP2R5C results in heart development defects, including the
formation of incomplete ventricular septum and a decrease in the number of ventricular
cardiomyocytes [79]. In addition, PPP2R5C knockout mice have a decrease in locomo-
tive coordination and gripping strength, which indicates that PPP2R5C is also required
for eﬃcient neuromuscular function. Finally, the knockout mice have also neonatal
growth deficiency, but survived knockout mice develop obesity after weaning and have
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31% more body weight at the age of 6 months. However, the exact mechanism causing
the obesity is still not clear. It could be a secondary consequence of reduced locomo-
tive activity or active metabolic change in a certain metabolic relevant organ. The
tissue-specific manipulation of PPP2R5C is needed for clarifying the multiple defects in
whole-body knockout mice.
Proteomic studies on PPP2R5C interacting partners reveals several interesting candi-
dates as PPP2R5C’s phosphatase substrates [80, 81]. A GST tagged PPP2R5C was
used to unravel its potential interaction partners by Mass Spectrometry approach [81].
And several proteins, such as the calcium pump SERCA2a and SERCA3a, are involved
in the calcium homeostasis. Interestingly, the SERCA2a has been recently identified
as the Serpin-interacting protein and shown that SERCA2a homolog in Drosophilla is
required for the fat storage in fat body (primitive organ with function of the liver and
adipose tissue in Drosophilla [82]) [83], which could potentially be conserved in mice and
fit with the obesity phenotype in PPP2R5C knockout mice [79]. The over-expression
of PPP2R5C in cultured myocytes impairs the cell contractility [81]. Another TAP
tagged PPP2R5C based proteomic strategy also found the Liprin a1 is interacting with
PPP2R5C independent of PP2A holoenzyme [80]. Liprin a1 is suggested to stabilize
PPP2R5C and regulate the focal adhesion [80].
Human PPP2R5C has been shown to be involved in regulating p53 tumor suppressor
activity upon DNA damage[9, 11]. After DNA damage, the PR56g containing PP2A
holoenzyme binds p53 and de-phosphorylates Thr55 of p53, which leads to the induction
of downstream transcriptional target p21 and following inhibition of cell proliferation
[9]. In addition, the interaction between PR56g and p53 upon DNA damage require the
ATM-dependent phosphorylation of Ser15 in p53 [11]. However, p53 protein sequence
alignment between human and mouse shows that the Thr55 in mouse is missing, and this
deletion rules out the possibility of mouse PR56g’s ability to inhibit the cell proliferation
via p53. Indeed, PPP2R5C knockdown in mouse cell lines has very mild eﬀects on
proliferation (circa 5% increase in total protein content, data not shown).
Human PPP2R5C is also involved in TCR-induced NF-kB activity [84]. The NF-kB is
activated upon T cell stimulation by complex phosphorylation event cascade. PPP2R5C
was found to be the negative regulator to fine-tune and terminate the NF-kB activation.
PPP2R5C silencing in stimulated primary human T cell causes increased phosphoryla-
tion in IKK and IkBa.
In this thesis project, I have explored the mammalian function of PPP2R5C in
metabolism control by tissue-specifically manipulating the expression of PPP2R5C in
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metabolically relevant tissues, such as the mouse liver. In addition, I have also employed
systematic approaches, such as the microarray analysis after PPP2R5C knockdown and
the proteomic study of PPP2R5C’s substrates, to investigate the potential mechanism
behind PPP2R5C’s metabolism control.
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2.1. Transcriptional change of PPP2R5C in response to
metabolic state or diseases
2.1.1. PPP2R5C splicing isoforms
In mice, PPP2R5C gene contains 4 splicing isoforms according to the NCBI’s genbank
annotation when I started the project. Initially, they were annotated as PPP2R5C
Variant 1–4 (named Variant 1–4 in the following sections). Now with deeper annotation,
there are 11 diﬀerent isoforms for the mouse PPP2R5C annotated in NCBI. The gene
structure is shown in Figure 2.1. Various isoforms of PPP2R5C shares the central exons
while diﬀers at both N and C terminal. From the structure of B56 containing PP2A
holoenzyme [50, 54], it is reasonable to postulate that central region of PPP2R5C is
more involved in the association to PP2A A and C subunit while the N and C terminal
are more engaged in fine-tuning the substrate specificity among isoforms.
2.1.2. Transcriptional change of PPP2R5C in response to
metabolic state
Since genes for metabolic regulators are often present in regulatory transcriptional feed-
back loops [85], I tested the relationship between the PPP2R5C expression and or-
ganismal nutritional status in various mice tissue samples by qPCR. Indeed, obese mice
lacking the leptin receptor (db/db) have significantly elevated levels of various PPP2R5C
mRNA isoforms in the liver (Figure 2.2). By the ANOVA (Analysis of Variance) anal-
ysis, at least for Variant 1, 2 and 4, there are significant increases in the transcriptional
level of PPP2R5C in the db/db mice liver comparing with the wt/wt mice. The Variant
3 has also shown a similar trend through not significant.
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Primer Set 4 shR3 shR6 miR12
Figure 2.1.: Mouse PPP2R5C gene structure. Four splicing isoforms, Variant 1 to 4, are displayed
with exons and introns according to NCBI genbank annotation. Primer sets for Variant
1–4 are also shown in their corresponding positions. miRNAs/shRNAs targeting the
common region of all isoforms, including shR3, shR6 and miR12, are also shown at their
relative positions. Adapted from NCBI genbank record of mouse PPP2R5C.
Another interesting finding in the liver PPP2R5C mRNA profile is that at least the
Variant 4 in wild type mice has a transcriptional increase in response to fasting. And
this response is reversed after 6-hour re-feeding. Though not significant, Variant 2 shows
a similar trend. Additionally, there are also some significant changes in Variant 1 within
wild type or db/db mice between diﬀerent nutritional statuses. However, these trends
are not clear in other isoforms and could be isoform-specific features.
In mouse abdominal white adipose tissues, there is also a significant trend in which most
of PPP2R5C variants have elevated mRNA levels in db/db mice, especially for Variant
4 (Figure 2.3). There is a significant transcriptional increase in db/db mouse adipose
tissues in most nutritional statuses even with larger standard deviation compared with
the liver PPP2R5C. This phenomenon is also validated to be true in another independent
qPCR analysis of mouse adipose samples, which was done by Katrin Straßburger in our
lab (data not shown). The same transcriptional change pattern shared between the liver
and adipose tissue PPP2R5C indicates a similar function performed by PPP2R5C in
the liver and adipose tissues. Interestingly, this match between adipose tissue and liver
had also been reiterated in the liver and subcutaneous adipose tissues in healthy human
controls and type 2 diabetic patients (See details in Section 2.7). This further indicates
the conserved function of PPP2R5C between mice and human, and raises the interest to
study PPP2R5C’s role in metabolic diseases, such as Type 2 Diabetes. Combining the
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Figure 2.2.: PPP2R5C is regulated in the mouse liver. Mouse PPP2R5C transcript variant 1–4 mRNA
levels in the liver from 8-12 week C57BL/6 wild type (WT) or db/db male mice under
diﬀerent nutritional statuses are shown here. Mice were fed with the normal chow diet
without limit ("Random"). For "Fasting" and "Refed", mice were first starved for 16 hours
and then allowed to the normal chow diet access for 6 hours. Error bar: std. dev. (this is
the same for all following figures with error bars). * and *** for p-value<0.05 and 0.001
by the t-test within each mice genotype (WT or db/db) and feeding regime (Random,
Fasting, and Refed) in R. p-value was adjusted by Benjamini-Hochberg procedure in R.
† and † † † for p-value<0.05 and 0.001 by ANOVA analysis with comparison between wt
and db/db mice.
function of the liver and adipose tissues [82]), and the obese phenotype in PPP2R5C
knockout mice and the fatty liver phenotype I have found after PPP2R5C knockdown
in liver (Figure 2.33), it is reasonable to hypothesize the similar molecular function of
PPP2R5C is shared by the mouse liver and adipose tissues.
PPP2R5C expression is nutritionally regulated in other metabolic relevant tissues such
as the muscle, although in an opposite way as that for the liver and adipose tissues.
In the mouse gastrocnemius muscle, PPP2R5C expression is increased upon re-feeding
(Figure 2.4). This is significant for all variants except Variant 1, though the trend is
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Figure 2.3.: PPP2R5C is regulated in mouse adipose tissues. Mouse PPP2R5C transcript variant
1–4 mRNA levels in adipose tissues from 8-12 week C57BL/6 wild type or db/db male
mice under diﬀerent nutritional statuses are shown here. Mice were fed with the normal
chow diet without limit ("Random"). For "Fasting" and "Refed", mice were first starved
for 16 hours and then allowed to the normal chow diet access for 6 hours. PPP2R5C
Variant 1–4 are referenced according to NCBI. † for p-value<0.05 by ANOVA analysis
with comparison between wt and db/db mice.
in almost all isoforms but Variant 3. The Variant 3 in both wt and db/db mice show an
increased expression upon re-feeding. In addition, Variant 3 has also increased in db/db
mice. In comparison with the liver and adipose PPP2R5C, The opposite transcriptional
response of PPP2R5C in the muscle during switch from fasting to re-feeding suggests
a distinctive role of PPP2R5C in metabolically relevant tissues under diﬀerent nutrient
conditions.
2.1.3. Transcriptional change of PPP2R5C in pathophysiology
I have also tested PPP2R5C expression levels among various mouse models for diﬀerent
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Figure 2.4.: PPP2R5C is regulated in the mouse muscle. Mouse PPP2R5C transcript variant 1–4
mRNA levels in the muscle from 8-12 week C57BL/6 wildtype or db/db male mice under
diﬀerent nutritional statuses are shown her. For "Fasting" and "Refed", mice were first
starved for 16 hours and then allowed to the normal chow diet access for 6 hours. * and
*** for p-value<0.05 and 0.001 by t-test within each mice genotype (WT or db/db) and
feeding regime (Random, Fasting, and Refed) in R. p-value was adjusted by Benjamini-
Hochberg procedure in R. † † † for p-value<0.05 by ANOVA analysis with comparison
between wt and db/db mice.
significantly reduced total mRNA level compared to control in the mouse liver from
mouse hepatosteatosis model (Figure 2.5). However, in other disease models, there are
no significant change in PPP2R5C mRNA level. In Dexamethasone induced mouse
type 2 diabetes model, no strong increase in liver PPP2R5C mRNA levels shows a
discrepancy with the genetic model of type 2 diabetes mouse model (db/db in Figure 2.2).
This diﬀerence could be due to diﬀerent mechanisms for developing symptoms of type
2 diabetes in the mouse [86, 87].
In sum, although I have no data suggesting that these transcriptional changes have any
functional relevance, these results suggest there might be links between PPP2R5C and
metabolic states or pathophysiological conditions. However, the total protein level of
24
2. Results

































































Figure 2.5.: PPP2R5C transcriptional change in diﬀerent pathophysiological conditions. Liver
PPP2R5C mRNA levels were evaluated by qPCR in control or treatment group for
the mouse model in Hepatosteatosis, Type I diabetes, and Type II diabetes. For Hep-
atosteatosis model, 16 week old male C57Bl6/J mice were fed with Methionine-Choline
Deficient (MCD) diet or control diet for 4 weeks. In the Type I diabetes model, mice
was treated with Streptozotocin (STZ) or control. For Type II diabetes model, mice was
treated with Dexamethasone (Dex) or control. ** for p-value<0.01 by t-test in R.
PPP2R5C in the liver of wt or db/db mice, measured by home-made antibody (Sec-
tion 2.2.2) for the mouse PPP2R5C, did not show a significant increase in the protein
level.
For potential upstream transcriptional regulator for mouse PPP2R5C, I have made a
transcription factor binding prediction [88] on mouse PPP2R5C promoter, which shows
several transcription factors, like NF-kB and HNF1a, are binding the mouse PPP2R5C
promoter in ChIP assays. PPP2R5C has been shown to be involved in NF-kB path-
way for T cell activation [84], and predicted NF-kB sites in PPP2R5C promoter in-
dicate feedback regulation from NF-kB pathway. HNF1a has been genetically linked
to maturity-onset diabetes of the young (MODY), and regulating several liver-specific
gene expressions, such as albumin [89]. HNF1a’s potentially binding sites on PPP2R5C
promoter indicate co-misregulation in diabetes.
Although the whole body knockout mouse model for PPP2R5C showed increased adi-
posity [79], distinct functions of PPP2R5C for metabolic homeostasis in a tissue-specific
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manner (in mammals) are widely unknown. A tissue-specific knockout or knockdown of
PPP2R5C would shed more light on its functions in metabolic control. Since PPP2R5C
has more than four splicing isoforms when the project was started, the primer sets 1–
4 used throughout the thesis are representing more than one transcript of PPP2R5C
(Figure 2.1). RNA sequencing for these samples would give more information about the
diﬀerential regulation of various splicing isoforms.
2.2. Antibody and virus preparation for PPP2R5C study
2.2.1. Selecting shRNA/miRNA for eﬃcient knockdown of
PPP2R5C
In order to characterize the mammalian function of PPP2R5C, I chose the mouse model
to decipher the molecular link for PPP2R5C in its potential role in metabolism. At
the first step, I designed diﬀerent shRNAs and miRNAs targeting common region of
all PPP2R5C mRNA isoforms from online RNAi design website from Invitrogen [90]
(final candidates used throughout the thesis are shown in Figure 2.1 and Table A.6).
Then I cloned shRNAs into pENTR U6, and miRNAs into pcDNA 6.2 GW EmGFP,
both were purchased from Invitrogen. To have a reporter for PPP2R5C knockdown
eﬃciency, I cloned PPP2R5C Variant 2 into 3′ UTR of renilla luciferase reporter (pRL-
CMV renilla) and co-transfected with expression vectors for shRNAs and miRNAs in
HEK293T cell. Knockdown eﬃciency was monitored for shRNAs and miRNAs as firefly
luciferase normalized activity (Figure 2.6).
After comparing the dynamic eﬃciency with diﬀerent shRNAs or miRNAs to reporter
plasmid ratios (Figure 2.6), shR3 is discovered to be the shRNA with strongest knock-
down eﬃciency in all transfection settings with diﬀerent ratios of shRNA expressing
plasmid and PPP2R5C Variant 2 knockdown eﬃciency reporter. miR2 is the current
best miRNA candidate while other two miRNAs have very mild knockdown eﬃciency.
Furthermore, knockdown eﬃciency was also cross-validated by Western Blot of HA-
tagged PPP2R5C Variant 2 (Figure 2.7a). Again, shR3 is shown to be the best shRNA
candidate with almost complete knockdown at protein level when co-expressed with
HA-tagged Variant 2. Thus, I chose shR3 to be the shRNA for PPP2R5C knockdown
in diﬀerent models, from cell to mouse. However, miRNA candidates have diﬀerent
performances in protein level knockdown (Figure 2.7a). miR3 has better knockdown
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Figure 2.6.: KD eﬃciency for shRNAs/miRNAs are measured on PPP2R5C variant 2 luciferase re-
porter. PPP2R5C variant 2 was cloned into 3′ UTR of firefly luciferase reporter (pRL-
CMV renilla). RL-Var2 reporter was used to evaluated shRNA/miRNA KD eﬃciency via
co-transfection with miRNA/shRNA expression construct at diﬀerent ratios in HEK293T
cell. Renilla luciferase (RL) activity was normalized against firefly luciferase (FL).
In order to achieve at least 80% knockdown eﬃciency both in protein and transcription
level, I did a bigger scale of searching miRNA candidate. I designed 12 new miRNAs
and cloned them as before. I also performed similar Western Blot validation across
various miRNAs (Figure 2.7b). In this experiment, miR12 was discovered to be the best
miRNA against PPP2R5C so far (only 5% Variant 2 left comparing with control miRNA
at protein level, Figure 2.7c), and chosen to be the miRNA for PPP2R5C knockdown
in vivo.
2.2.2. Generating Guinea Pig antibody for endogenous PPP2R5C
detection
To monitor PPP2R5C’s endogenous regulation as well as the knockdown eﬃciency, I had
to generate a specific antibody for mouse PPP2R5C. Although there was commercial
antibody against mammalian PPP2R5C available from Abcam, I tested it and found
it was failed in the specificity test, in which Variants 1–4 were over-expressed in mouse
Hepa 1-6 cells to see any increased band matched with the size of PPP2R5C protein.
Then I decided to make a polyclonal antibody against mouse PPP2R5C in the lab. I
chose Variant 3 to be the immunizing antigen in guinea pig due to its smaller size, and
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(a) shRNA/miRNA KD eﬃciency
by western blot
(b) New set of miRNAs’ KD eﬃciency by western blot




















































Figure 2.7.: Knockdown (KD) eﬃciency validated by western on PPP2R5C. (a–b) PPP2R5C KD
eﬃciency by miRNAs and shRNAs. miRNA or shRNA construct was co-transfected with
HA-tagged Variant 2 of PPP2R5C at diﬀerent ratios in 293T cell. Total lysates after
3-day transfection were used to measure KD eﬃciency by blotting with a–HA antibody.
(c) Quantification of miRNAs KD eﬃciency on PPP2R5C in Image J.
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Figure 2.8: PPP2R5C Variant 3 (V3) was
cloned into pETM-11 (EMBL protein
expression/purification facility) to
be expressed in E. coli. BL21-
CodonPlus(DE3)-RIL strain. pETM-
11 with V3 was electroporated into
RIL and induced at 1 mM IPTG (Iso-
propyl b-D-1-thiogalactopyranoside)
at 18 ◦C overnight. 1 mL bacteria
before induction (U) and after
induction (I) were taken to control
the induction eﬃciency. Bacteria
pellet after induction was lysed in
lysis buﬀer (10mM MgCl2, 150mM
NaCl, 10mM Imidazole, 20mM Tris
pH 7.5) with 1 mg/ml Lysozyme,
and separated into insoluble (P) and
soluble fraction (S). Soluble fraction
was loaded onto Ni-NTA column, and
the flow-through fraction (FT) was
collected. Final elute was collected
in lysis buﬀer with 500mM Imidazole
(E). All fractions from purification
were run in 12% SDS-PAGE gel with
protein marker (M) and stained with
GelCode Coomassie stain.
potentially better solubility in bacteria than other isoforms. The recombinant Variant 3
was successfully produced in bacteria with a 6×His tag. The IMAC (Immobilized metal
ion Aﬃnity Chromatography) purification gave a good amount enough for immunization
(~1 mg). And the purity of recombinant Variant 3 was also good enough to have high
specificity during antibody production (circa 89% in Coomassie brilliant blue staining,
Figure 2.8).
Polyclonal antibody production in guinea pig was produced with Freund’s adjuvant. Af-
ter 4th boosting immunization, I collected sera from guinea pig by heart puncture under
animal welfare regulation in Germany, and with the generous help from Stefan Fößel in
DKFZ’s animal core facility. I tested the specificity of anti-sera for PPP2R5C in both en-
dogenous PPP2R5C knockdown (KD) and diﬀerent PPP2R5C isoforms over-expression
(Figure 2.9). Even at 1:5000 dilution, PPP2R5C anti-sera could still detect various
PPP2R5C isoforms’ over-expression and the endogenous knockdown of PPP2R5C by
the adenovirus-packaged shR3 in Hepa 1-6.
Interestingly, the adenovirus-packaged shRNC, which is a non-targeting scramble
shRNA, strongly decreases the PPP2R5C protein level, especially for the band size-
matched with Variant 3. And this is also true for the transcriptional level of PPP2R5C
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Figure 2.9.: Antibody specificity for PPP2R5C in Hepa 1-6 lysates. (a) Variant 1–4 (V1–4) were
over-expressed in Hepa 1-6 for 3 day. Total lysates from control (no over-expression) or
V1–4 were submitted for Western Blotting by guinea pig antibody against PPP2R5C.
V1–4 were corresponding to 3 lower bands. The most upper band could be non-specific
band or other protein with high PPP2R5C homology, such as PPP2R5D. (b) knockdown
eﬃciency on endogenous PPP2R5C by adenovirus packaged with shR3. 3 lower bands is
size matched to V1–4 and showed a clear reduction in shR3. Band corresponding to V3
already showed reduction in shRNC comparing to PBS control.
(Figure 2.10). Specifically, Variant 3 mRNA level drops to around 40% from low dosage
(MOI (Multiplicity of Infection) = 10) to high dosage (MOI = 100, 200) of adenovirus
infection. This indicates non-specific knockdown eﬀect on Variant 3. It is known the
adenovirus has strong immunogenic eﬀect [91]. Strong immunogenicity could initiate
some inflammation response which then aﬀect the expression of PPP2R5C Variant 3.
Interestingly, PPP2R5C has recently been shown to be involved in NF-kB mediated
inflammation response [84]. The PPP2R5C suppression upon high dose adenovirus in-
fection suggests a feedback loop of PPP2R5C transcription in the immune response.
This virus-mediated suppression of PPP2R5C could potentially controlled by NF-kB
pathway on the predicted NF-kB sites in its promoter [88].
2.3. PPP2R5C negatively regulates glycolysis and
lipogenesis
2.3.1. PPP2R5C KD in Hepa 1-6 increases glycolysis
With eﬃcient in vitro knockdown tools for PPP2R5C, I firstly studied the Hepa 1-6 to
decipher the functional role of PPP2R5C, especially in metabolism control. As shown
in Figure 2.9, endogenous PPP2R5C could be successfully knocked down at eﬃciency
of 80% by adenovirus-packaged shR3. After 3-day infection, mutant Hepa 1-6 cells with
PPP2R5C knockdown show a clear increase in glycolysis, which is initially observed
as deeper brownness of culture media in PPP2R5C KD Hepa 1-6 cells. Indeed, the
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Figure 2.10.: Knockdown profile of endogenous PPP2R5C isoforms in Hepa 1-6 cells. Adenovirus
with diﬀerent MOIs (10, 100, 200) was diluted in PBS and infecting Hepa 1-6 for 3
days. The quantitative PCR analysis of PPP2R5C Variant 2/3/4 shows nice knockdown
eﬃciency profile, which is dependent on MOI for all isoforms. MOI at 10 shows almost
no reduction in mRNA level for all isoforms. MOI at 100 and 200 show a similar level of
significant knockdown. Variant 3 is sensitive to control Adenovirus (shRNC) and shows
a reduction in mRNA level at MOI of 100 or 200.
glucose consumption assay (Figure 2.11a) indicates a strong increase in the glycolysis
rate even in the last 24 hour of infection period. Accordingly, the lactate production
(Figure 2.11b) has also similar extent of the increase as that in the glucose consumption.
These pieces of evidence demonstrate that PPP2R5C could be a negative regulator of
glycolysis.
In addition, I also employed seahorse experiment to confirm the increased glycolysis
phenotype after PPP2R5C knockdown. When normalized to cell nuclei counting by
DAPI staining, Hepa 1-6 knockdown cells have increased AUC (Area Under Curve)
of glycolysis rate comparing with control adenovirus infected cells (Figure 2.12). The
increase becomes statistically significant after oligomycin is added, which boosts the
maximal glycolytic activity. Combining with data from glucose consumption and lactate
production (Figure 2.11), it is clearly demonstrated that the PPP2R5C knockdown















































Figure 2.11.: PPP2R5C knockdown promotes the glucose consumption and lactate production in
Hepa 1-6. Hepa 1-6 cells were infected with adenovirus packaged either with non-
targeting scramble shRNA (shRNC) or PPP2R5C targeting (shR3) at MOI of 100 or
200 for 3-day knockdown. Infection was done in first 24 hours and then Hepa 1-6 cells
were washed by fresh medium. The glucose consumption (a) and lactate production
(b) were measured in the last 24-hour window of knockdown. They were background-
subtracted from glucose and lactate concentration in fresh medium and normalized to
























Figure 2.12.: PPP2R5C Knockdown promotes glycolysis in seahorse experiment. Adenovirus with
MOI=100 was diluted in PBS and infected Hepa 1-6 for 2 days. Then infected Hepa
1-6 was digested with trypsin from the culture plate and re-plated in 96-well plate with
balanced cell number between diﬀerent groups (Control KD for shRNC, and PPP2R5C
KD for shR3). Glycolysis activity was measured on seahorse instrument with glycolysis
stress kit. Glucose, oligomycin and 2-Deoxy-Glucose were added at the time of vertical
dashed line according to the protocol in the kit. The extracellular acidification rate
(ECAR, mpH/min) was recorded as an indirect readout for intracellular glycolysis rate.

































Figure 2.13.: Single live Hepa 1-6 cell filtering in FACS by R. X-coordinate is marker for cell size
(FSC-W, Foward-ScatteredWidth), and y-coordinate is cell granularity (SSC-A, Side-
Scattered Area). Hepa 1-6 with stable shRNAs (shR3 or shR6) or not were induced
at 30 µg/mL cumate (1x, 0x for DMSO control) for 3 day and then starved in serum-
free DMEM overnight. shR3-4 and shR6-5 were single clone for shR3 and shR6. Then
these cells were sensitized in KRPH (Krebs-Ringer-Phosphate-HEPES) buﬀer for 1 hour
and followed by 20 min incubation with 100 µM 2NBDG. Finally, Hepa 1-6 cells were
digested with trypsin for 3 minutes and subjected to FACS analysis. Single live Hepa
1-6 cells were clustered in FSC-SSC scatter plot and filtered out in R by using package
flowCore (indicated by red circle on scatter plot). Single live cell population and doublet
Hepa 1-6 cells are pointed with arrows.
2.3.2. PPP2R5C KD promotes glucose uptake rate in Hepa 1-6
Although PPP2R5C is shown to be a negative regulator of glycolysis, it is still not clear
the increased glucose consumption is due to increased cell number with the same glucose
uptake rate or increased glucose uptake rate within the same number of cells. On one
hand, the total protein content after PPP2R5C knockdown has not changed between
control and PPP2R5C knockdown cells (data not shown), which indicates no strong
increase in cell proliferation. On other hand, I employed a short-term glucose uptake
assay to assess the glucose uptake activity of Hepa 1-6 by measuring 2NBDG uptake in
20 min via FACS (Figures 2.13 to 2.15), in order to eliminate any glucose uptake eﬀect
from increasing cell number during assay time in Figure 2.11a. 2NBDG is a fluorescent
2-deoxyglucose analog which was widely used to monitor glucose uptake rate [92, 93,
94, 95, 96].
Additionally, I cloned 2 sets of shRNAs (shR3 and shR6) into a miR30-based inducible
shRNA expression vector [97, 98], and stable Hepa 1-6 cell lines harboring genome-
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Figure 2.14: Density plot of Hepa 1-6 cell with
positive 2NBDG uptake. Filtered
single live Hepa 1-6 cells were com-
pared for 2NBDG fluorescence in-
tensity between Hepa 1-6 cell with
2NBDG incubation and the one
without 2NBDG incubation to calcu-
late a threshold for 2NBDG uptake
(left vertical line). Median intensity
in Hepa 1-6 without cumate induc-
tion (right vertical line) was calcu-
lated for better comparison between
diﬀerent cell lines. shR3-4 and shR6-
5 were single clone for shR3 and
shR6. 0x and 1x were DMSO con-
trol and 30 µg/mL cumate induction
for 3 days. The fluorescence inten-
sity was asinh transformed to have
a nice representation of intensity at
diﬀerent magnitudes.
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integrated inducible shR3 or shR6 were generated after puromycin selection. The stable
inducible cell lines were used as cross-validation for results from the adenovirus-packaged
shR3, and supposed to eliminate any potential virus-mediated eﬀects given the fact of
high immunogenicity of adenovirus and non-specific down-regulation on Variant 3 of
PPP2R5C by adenovirus. The shR3 and shR6 expression were induced by 30µg/mL
cumate for 3–4 days to achieve similar extent of knockdown eﬃciency as that in the
adenovirus packaged shR3.
I analyzed all the data from FACS either in flowCore [99], flowStats [100] and flowViz
[101] package in R, and validated the analysis again in FlowJo. There are mainly two
populations in all cell lines based on the size distribution (from empty Hepa 1-6 to two
stable inducible shRNA cell lines) (Figure 2.13). And these two populations have not
changed after shRNA expression by induction with 30 µg/mL cumate, which indicates no
significant cell morphological change after PPP2R5C knockdown. Based on particle size
(FSC), it is clear that the population at the left is single live cells, and the population on
the right is doublet Hepa 1-6 cells potentially from incomplete digestion by trypsin. For
accurate single cell glucose uptake measurement, I chose the single live cell population
for glucose uptake assay by FACS.
In the first step, single live Hepa 1-6 cells were filtered out based on size (red circled
area in Figure 2.13) with a 2D-normal distributed contour from flowCore package. Then,
single live Hepa 1-6 cells were analyzed to calculate the proportion of 2NBDG positive






























Figure 2.15.: 2NBDG uptake in Hepa 1-6 upon PPP2R5C knockdown. FACS data for 2NBDG uptake
in empty Hepa 1-6, Hepa 1-6 with inducible shR3 and 6 (single clone shR3-4 and shR6-
5) were induced at DMSO (0x) or 30 µg/mL cumate (1x) and analyzed as described in
Figure 2.14 and Figure 2.13. ** and *** for p-value<0.01 and 0.001 by t-test in R.
asinh transformed density map of all 2NBDG positive staining, there is a obvious red-
shift in the density map after PPP2R5C knockdown (Figure 2.14), and almost all single
live Hepa 1-6 cells have positive 2NBDG uptake. For empty Hepa 1-6 cells, there is
no red-shift in density map after the cumate induction. These data clearly show that
PPP2R5C knockdown could increase glucose uptake even in very short time period, such
as 20 minutes. The quantification of median fluorescence intensity (MFI) is normalized
and showed in Figure 2.15. The same phenotype has also been observed in a third
independent shRNA for PPP2R5C (shR8, data not shown).
In mouse primary hepatocytes, there is also a nice cross-validation of glucose uptake
phenotype observed in Hepa 1-6 cells (Figure 2.16). At two diﬀerent nutritional statuses,
either starved for serum or non-starved, the glucose uptake, which is determined by
FACS measurement of 2NBDG uptake as that in Figure 2.15, shows clear trend of
increase in PPP2R5C knockdown cells comparing with non-targeting shRNA control
cells. For non-starved condition, the increase is statistically significant. Again, the non-
targeting shRNA control adenovirus still has some non-specific virus eﬀect on glucose




























Figure 2.16.: 2NBDG uptake in mouse primary hepatocytes upon PPP2R5C knockdown by the ade-
novirus with shRNC or shR3. FACS data were collected and analyzed as described in
Figure 2.15. * for p-value<0.05 by t-test in R. n=3.
2.3.3. PPP2R5C deficiency promotes de novo lipogenesis
Another interesting phenotype by PPP2R5C knockdown is the increased lipid storage in
the cultured primary hepatocytes (Figure 2.17). For cultivated mouse primary hepato-
cytes, I have received two sources of them, from Prof. Herzig’s and Prof. Klingmüller’s
lab especially. These two sources of hepatocytes were prepared in their correspond-
ing lab with the same protocol of isolation. However, hepatocytes from Prof. Kling-
müller’s lab were additionally counted for living cell by trypan blue staining. With
these two diﬀerent sources of mouse primary hepatocytes, the PPP2R5C knockdown
via adenovirus-packaged shR3 shows a significant increase (approximately 2-fold) in the
triglyceride storage comparing to the non-targeting shRNC or PBS control. Although
relative extent of lipid storage increase is proportionally augmented with the duration
of knockdown, prolonged in vitro cultivation of primary hepatocytes sometimes ended
up with de-diﬀerentiation of the hepatocyte. The de-diﬀerentiated primary hepatocytes
usually show distorted and shrunken cell shape. The lipid storage increase phenotype
could not be observed under this condition, such as 3-day adenovirus infected hepato-
cytes from Prof. Herzig’s Lab at DKFZ ("Herzig 3 Day" in Figure 2.17).
In contrary to the shRNC eﬀect on glycolysis phenotype, the non-targeting scramble
shRNA showed no eﬀect on the lipid storage when that was comparing with PBS con-

















































Figure 2.17.: PPP2R5C knockdown increases lipid storage in primary hepatocytes. Mouse primary
hepatocytes were kindly provided from two sources, routine hepatocyte isolation from
Prof. Klingmüller’s lab and Prof. Herzig’s lab, in order to cross-validate the lipid
phenotype. They share the same isolation protocol. I collected mouse hepatocytes from
one mice after their routine hepatocyte isolation, and infected these primary hepatocytes
with adenovirus at the same condition as in Figure 2.16. Triglycerides were measured
after 2-day or 3-day infection. Hepatocytes from Prof. Klingmüller’s lab were kindly
prepared by Dr. Lorenza Alice D’Alessandro, and hepatocytes from Prof. Herzig’s lab
were kindly prepared by Dr. Mauricio Berriel Diaz. Lipid fraction was extracted by
methanol-chloroform method [102] and measured for free glycerol released from lipase
digestion. *, ** and *** for p-value<0.05, 0.01 and 0.001 by t-test in R, n=3.
glycolysis and lipid storage after PPP2R5C knockdown.
In addition to the lipid storage and glycolysis phenotype, the PPP2R5C knockdown in
primary hepatocyte has no eﬀect on the ATP level (Figure 2.18a) and glycogen level
(Figure 2.18b). This indicates the excessive energy from the increased glucose uptake is
shunted into the energy storage as triglyceride storage, but not as the ATP or glycogen
in cultivated primary hepatocytes.
Moreover, the lipid storage phenotype in PPP2R5C knockdown is also conserved in
another cell type, Hepa 1-6 cells (Figure 2.19). Even treated with mTOR inhibitor ra-
pamycin, the lipid storage phenotype is still present without compromising its increase.
This evidence indicates the mechanism how PPP2R5C aﬀect lipid storage is either at the
downstream of mTOR or in parallel with mTOR. It has been shown that the mTORC1
activation leads to the increase in glycolysis and lipogenesis via the downstream activa-
tion of HIF1a and SREBP-1 [22]. The increased glycolysis and lipogenesis in PPP2R5C

























































Figure 2.18.: PPP2R5C knockdown does not change the ATP level (a) or the glycogen storage (b)
in mouse primary hepatocytes. Primary hepatocytes were infected with the adenovirus



































Figure 2.19.: PPP2R5C knockdown increases lipid storage in Hepa 1-6 independently of mTOR. Hepa
1-6 were infected with adenovirus at the same condition as in Figure 2.11. Lipid fraction
was extracted by methanol-chloroform method and measured for free glycerol released
from lipase digestion. *, ** for p-value<0.05, 0.01 by t-test in R, n=3.
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Figure 2.20.: Free fatty acid in culture medium is not responsible for increased triglyceride storage
inside Hepa 1-6. (a) Free fatty acid from culture media was enriched by methanol-
chloroform method [102] and uptake was calculated from the diﬀerence in free fatty
acid between fresh medium and medium after 3-day culturing. (b) Intracellular free
fatty acid level. Hepa 1-6 cells were infected with adenovirus at the same condition as
in Figure 2.15. * for p-value<0.05 by t-test in R, n=3.
In order to further clarify the lipid storage phenotype is a result of the increased de novo
lipogenesis but not the re-esterification of absorbed free fatty acids, I measured the free
fatty acid uptake from culture media and the intracellular free fatty acid in Hepa 1-6 cells
upon PPP2R5C knockdown (Figure 2.20). Neither of them is increased after PPP2R5C
knockdown. No increase in free fatty acid uptake suggests the accumulated lipid storage
could come from de novo lipogenesis. If comparing the relative concentration of free
fatty acid uptake during 3-day infection with that for fatty acid equivalent increment in
triglyceride after PPP2R5C knockdown (approximately comparing 6 nmol/(mg protein)
with 30 nmol/(mg protein), 1 molecule of triglyceride consists of 3 molecules of fatty
acid), it is very unlikely that the increased triglyceride storage phenotype comes from
the increased re-esterification of absorbed free fatty acids, but rather from de novo
biosynthesis. Also, the slight decrease in the intracellular free fatty acid concentration
after PPP2R5C implies a higher flux from intracellular free fatty acid toward triglyceride
synthesis when comparing with shRNC.
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2.4. PPP2R5C in vivo knockdown promotes glucose
uptake, triglyceride synthesis
It was interesting to know the PPP2R5C’s role in a cellular model, such as the Hepa 1-6
or mouse primary hepatocyte (Section 2.3). Data in cell culture suggested PPP2R5C’s
potential role in metabolism is shunting the absorbed glucose into lipid storage in a cell-
autonomous fashion. But it was always more physiological-relevant when investigating
the PPP2R5C’s function in metabolism in vivo. To achieve this purpose, I employed
adeno-associated virus (AAV) to specifically express the miRNA targeting PPP2R5C
(miR12, see Figure 2.1 and Table A.6) in the mouse liver and perform a long-term knock-
down in vivo as described [103]. Previously, the miR12 was selected as miRNA candidate
based on its highest eﬃciency in knockdown tested in HEK293T cell (Figure 2.7c). The
AAV packaged miR12 was produced from Vector Biolabs (Philadelphia, USA) due to
the insuﬃcient in-house virus production yield. I performed a pilot mouse experiment to
evaluate the in vivo knockdown eﬃciency in the mouse liver. From the qPCR analysis of
total PPP2R5C mRNA (Figure 2.21a) and protein level (Figure 2.21b), there is a strong
reduction in both transcriptional and protein level. This AAV packaged miR12 gave me
the appropriate tool to have a liver-specific manipulation of the mouse PPP2R5C.



























(b) Knockdown eﬃciency in protein level
Figure 2.21.: PPP2R5C knockdown eﬃciency in vivo. (a) miR12’s in vivo knockdown eﬃciency was
compared with the non-targeting control miRNC after 2 week AAV injection. qPCR was
performed with the probe set for total mRNA of PPP2R5C in the liver. (b) Knockdown
eﬃciency was evaluated at protein level. The liver endogenous PPP2R5C was detected
by the home-made guinea pig antibody against it. Non-specific binding band was showed
at bottom as the loading control. n=5 for qPCR analysis.
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2.4.1. PPP2R5C knockdown has no impact on animal health
With the knowledge of miR12’s in vivo knockdown eﬃciency, I performed another mouse
experiment with longer AAV infection in order to see the relatively long term eﬀect of
PPP2R5C in metabolism. With 7 weeks of PPP2R5C knockdown in the mouse liver,
there is no severe side eﬀect from AAV infection, which could be demonstrated by the
low level of serum ALT level and no further increase in knockdown mice (Figure 2.22).
ALT is an enzyme mainly expressed in the liver, much less expressed in kidney, heart,
muscle. The serum ALT level is normally low, and only become high when the liver
is damaged or diseased (leakage across damaged hepatic cell membrane). Serum ALT
level around 20 U/L was much lower than that from mice suﬀering liver injury (several





















Figure 2.22.: Serum ALT (Alanine Aminotransferase) level indicates no liver injury. 8-10 week
CL57BL/6 male mice were injected with adeno-associated virus packaged miRNA
against mouse PPP2R5C (miR12) or scramble miRNA (miRNC) at 1×1011 viral par-
ticles/mouse via tail injection in 100 µL PBS. And injected mice was sacrificed after
7-week knockdown. Before sacrificing, mice were divided into diﬀerent groups for var-
ious treatments, including ad libitum fed (Random), 16 hour fasting (Fasting), and 16
hour fasting followed by 6 hour feeding (Refed). 5 µL serum was used to measure ALT
enzymatic activity. n=5 or 6.
During the AAV infection, mice from control and knockdown group (miRNC vs miR12)
have also no significant diﬀerence in the body weight growing profile (Figure 2.23),
which indicates no strong whole body growth change after the liver-specific PPP2R5C
KD. Furthermore, I have also performed the body composition analysis in these mice
every 2 or 3 week by using echoMRI measurement. There is also no significant diﬀer-
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ence in fat (Figure 2.23) and lean mass (data not shown) profile between control and
knockdown group. Although these mice subjected into fasting before final preparation
show some diﬀerence before virus injection, and the diﬀerence remained constant during
knockdown and contributed to the overall baseline diﬀerence in control and knockdown
group. After sacrificing, I also measured the mouse abdominal white adipose tissue
weight (Figure 2.24). There is also no change in abdominal white adipose tissue weight
upon PPP2R5C KD. In summary, 7-week liver-specific PPP2R5C knockdown via AAV
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Figure 2.23.: Body weight and fat composition profile have no change after PPP2R5C knockdown.
Mice in Figure 2.22 were measured for body weight at each week (left panel). Time 0
was the body weight before virus injection. Whole body fat composition was calculated
from fat content normalized to body weight at each time point (right panel). Week 0
indicated fat composition before virus injection. n=5 or 6.
2.4.2. PPP2R5C KD promotes glucose uptake in vivo with better
insulin sensitivity
Since the liver is important for maintaining euglycemia, especially in the postprandial
phase [26], I measured the blood glucose level for ad libitum feeding ("Random"), 16 hour
fasting ("Fasting"), and 16 hour fasting followed by 6 hour refeeding ("Refed") in control
and knockdown mice (Figure 2.25). Surprisingly, there are no significant decreases in
all three conditions, even given that PPP2R5C KD in cultivated hepatocytes increased


























Figure 2.24.: Abdominal white adipose tissue (Abd.WAT) has no change after PPP2R5C knockdown.
Mice were the same as Figure 2.22. After mice were treated with diﬀerent nutritional
statuses (Random, Fasting and Refed), Abd.WAT tissue was collected from each mouse
and weighted before stored in -80◦C. n=5 or 6.
Although there is no change in blood glucose level after PPP2R5C knockdown, the serum
insulin concentration drops almost 2-fold after PPP2R5C knockdown (Figure 2.26) when
mice are fed ad libitum. In Fasting and Refed group, serum insulin levels are also de-
creased comparing with control mice. The decreased circulating insulin levels indicated
the increased insulin sensitivity. Indeed, the insulin sensitivity index [105] in random
and refed group are also increased in PPP2R5C knockdown mice (Figure 2.27).
Besides the increased insulin sensitivity, glucose uptake capacity is also increased in 6
hour fasted mice after PPP2R5C knockdown, which is shown by the improved glucose
tolerance in glucose tolerance test (GTT) (Figure 2.28). This piece of data is nicely
correlated with the increased glucose uptake and glycolysis in cellular models (Hepa 1-6
cells and mouse primary hepatocytes, Figures 2.12, 2.15 and 2.16). AUC analysis for
GTT data also demonstrates the decreased AUC in PPP2R5C knockdown (Figure 2.29).
Although the absolute serum insulin levels from the same mouse in GTT experiment
could not be calculated due to their level are below the limit of detection, raw O.D. 450
is used to estimate relative serum insulin level (Figure 2.30). And the relative serum
insulin levels in PPP2R5C knockdown mice are even lower than control mice, given
that they still have quicker glucose clearance rate (Figure 2.28). In sum, these data


























Figure 2.25.: Blood glucose level has no change after PPP2R5C knockdown. Mice were the same as























Figure 2.26.: Serum insulin drops after PPP2R5C knockdown in ad libitum fed (Random) or 6-hour
Refeeding after 16-hour fasting. Serum insulin was measured using ELISA kit for mouse
insulin, and standard curve for ELISA was fitted from serial diluted insulin standards
(0.1-6.9 ng/mL) with 5-parameter logistic model in R. * for p-value<0.05 by t-test in





















Figure 2.27.: Insulin sensitivity index (ISI) increases after PPP2R5C knockdown in ad libitum fed
(Random) or 6-hour re-feeding after 16-hour fasting. ISI index was calculated from the
inverse of the product between blood glucose concentration and insulin concentration.
* for p-value<0.05 by t-test in R for comparing miR12 to miRNC for each nutrition
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Figure 2.28.: Glucose tolerance test (GTT) shows better glucose tolerance in PPP2R5C KD. GTT
was performed 4 weeks after virus injection at dosage of 2g glucose/kg body weight.
Glucose was solubilized in PBS and injected intraperitoneally. Blood glucose before
injection was recorded as it for time 0 min, and also measured at time 20, 60, 90, 120
and 150 min. * and ** for p-value<0.05 and 0.01 by Wilcoxon signed-rank test in R
for comparing miR12 to miRNC. n=12. Repeated Measures ANOVA in R showed a
significant diﬀerence in blood glucose changing profile with p-value of 0.0098.
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Figure 2.29: Area Under Curve (AUC) analysis
for GTT blood glucose profile in Fig-
ure 2.28. ** for p-value<0.01 by t-
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Figure 2.30.: Serum insulin relative level decreases in PPP2R5C. Due to O.D. 450 for some mice were
even below the blank sample in the standard curve, absolute serum insulin level could
not be calculated properly. Instead, raw O.D. 450 was employed to show the relative
serum insulin level in GTT samples. * and ** for p-value<0.05 and 0.01 by two-sample
t-test in R for comparing miR12 to miRNC. Repeated Measures ANOVA in R showed




2.4.3. PPP2R5C KD promotes anabolic changes in liver
The increased glucose uptake in the liver after PPP2R5C KD indicates a more anabolic
metabolism in hepatocytes in knockdown mice. In agreement with this, the liver has
significant weight gain upon PPP2R5C knockdown in all groups (Figure 2.31), instead
of no systematic anabolic change in whole body weight or size of tissues beside the liver
(Figures 2.23 and 2.24). The increase in Fasting and Refed group are even stronger
than that in the Random group. In the postprandial phase, glucose is absorbed by
hepatocytes to synthesize glycogen and lipids [35, 106]. The increase could be partially
explained by the increase in liver glycogen (Figure 2.32) and triglyceride (Figure 2.33),
even all these data are normalized to the liver weight. Without normalization, the
increase in total liver triglyceride and glycogen would be even more. Most strikingly,
although glycogen levels drop in control livers upon fasting, as they enter a catabolic
state to provide the rest of the organism with glucose, PPP2R5C knockdown livers
























Figure 2.31.: Liver weight increases after PPP2R5C knockdown in all nutritional status. Mice were
the same as in Figure 2.22. Dissected liver was weighted before aliquoting for cryosec-
tion, paraformaldehyde fixation and -80◦C storage. n=5 or 6.
Glucose is also used by hepatocytes for lipid biosynthesis. Combining data from GTT
experiment (Figure 2.28) and cell-autonomous increased glucose uptake lipogenesis in in
vitro cultivated hepatocytes (Figures 2.16 and 2.17), implies the increased glucose uptake
in the liver would also possibly shunted into lipid synthesis pathway. In agreement with
this, mice with PPP2R5C KD have significantly elevated triglyceride levels in their livers
































Figure 2.32.: Liver glycogen increases after PPP2R5C knockdown in fasting and refed. Mice were the
same as in Figure 2.22. Frozen liver sample was pulverized in the tissue homogenizer
with pre-cooling in liquid nitrogen. Glycogen was extracted from ~150 mg liver powder
and measured for glucose level after overnight amyloglucosidase digestion. * and ** for
p-value<0.05 and 0.01 by t-test in R for comparing miR12 to miRNC for each nutrition
group. n=5 or 6.
mice in the random group, liver triglyceride levels in these two control mice are also
higher, probably by passively increasing the re-esterification of NEFA into triglycerides
in these two control mice. By ANCOVA (Analysis of Covariance) analysis with the liver
NEFA as covariate, liver triglyceride in knockdown mice in the random group is found
to be significantly higher (p-value=0.04).
Although this lipid storage eﬀect is visible after 7 week PPP2R5C knockdown (Fig-
ure 2.33), it is even more pronounced after 2 week knockdown (Figure 2.35), possibly
due to the reduced knockdown eﬃciency upon counter-regulation over time, or com-
pensatory regulatory mechanism developed over time. However, Oil Red O staining on
the liver sample does not show visible change in lipid droplet (data not shown), which
indicates the increased triglyceride storage is mainly microvesicular lipid droplets which
are not easily visible under microscope after Oil Red O staining.
One possible explanation for the increased liver triglyceride levels could be the reduced
liver fatty acid b-oxidation. However, the serum ketone body concentration of total ke-
tone body species and hydroxybutyrate are maintained at the same level after PPP2R5C
KD (Figures 2.36 and 2.37) at various feeding conditions. Total ketone body concentra-
tion are increased in the fasting group and decreased after refeeding for both control and






























Figure 2.33.: Liver triglyceride increases after PPP2R5C knockdown in random but decreases in
fasting. Mice were the same as in Figure 2.32. Lipid fraction was extracted from
liver by methanol-chloroform and triglyceride was measured as free glycerol released
from lipase digestion. † for p-value<0.05 for ANCOVA analysis for comparing liver
triglyceride between miRNC and miR12 in random fed, in which liver non-esterified


































Figure 2.34.: Liver NEFA level has no significant change after PPP2R5C knockdown in all feeding
regimes. Mice were the same as in Figure 2.32. Lipid fraction was extracted from liver
by methanol-chloroform and NEFA was measured. n=5 or 6.
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Figure 2.35: Liver triglyceride increases after
PPP2R5C knockdown in random
fed. 8-10 week CL57BL/6 male
mice were injected with adeno-
associated virus packaged miRNA
against mouse PPP2R5C (miR12) or
scramble miRNA (miRNC) at 0.5 or
1×1011 viral particles/mouse via tail
injection in 100 µL PBS. And In-
jected mice was sacrificed after 2-
week knockdown. For liver triglyc-
eride analysis, data from low and
high dose virus injection were com-
bined. ** for p-value<0.01 by t-



























activity in the liver and the following ketone body concentration in the circulation. Ad-
ditionally, the hydroxybutyrate concentration normalized to total ketone body also did
not show any relative change upon PPP2R5C KD (Figure 2.38). Circulating ketone
body levels are not changed upon PPP2R5C KD is indicating that accumulation of hep-
atic triglyceride levels are not likely due to the impaired utilization in b-oxidation but
presumably due to the increased de novo lipogenesis, which have been demonstrated in




























Figure 2.36.: Serum total ketone body (TKB) does not change upon PPP2R5C knockdown in all
feeding regimes. Mice were the same as in Figure 2.32. n=5 or 6.
































Figure 2.37.: Serum hydroxybutyrate (HB) concentration does not change upon PPP2R5C knock-

















Figure 2.38.: Serum HB to TKB ratio does not change upon PPP2R5C knockdown in all feeding
regimes. Mice were the same as in Figure 2.32. n=5 or 6.
51
2. Results
fasting (Figure 2.33). I have tested if this could be due to increased lipid secretion from
the liver. Indeed, the serum triglyceride in fasting and refed group after PPP2R5C
KD are increased significantly (Figure 2.39). This leads to a drop not only in triglyc-
eride but also cholesterol in PPP2R5C knockdown livers upon fasting and refed (Fig-
ure 2.45). This raises the possibility of co-transportation of triglyceride and cholesterol
out from the liver in the form of VLDL. Upon refeeding, PPP2R5C knockdown livers re-
accumulated triglycerides very rapidly, reaching control levels within 6 hours of refeeding
(Figure 2.33), consistent with elevated lipid biosynthesis rates in PPP2R5C knockdown
livers. Taken together, PPP2R5C knockdown livers have more glucose uptake than con-
trol livers, thereby produce more triglycerides, and secrete elevated lipid amounts into
circulation. The steady state levels of triglyceride in PPP2R5C knockdown livers likely
reflect this balance between increased biosynthesis and increased secretion, leading to a
drop in the liver triglyceride upon fasting when less dietary glucose is available for lipid
biosynthesis. If the serum triglyceride and liver triglyceride are considered together, the



























Figure 2.39.: Serum triglyceride increases after PPP2R5C knockdown in fasting and refed. Mice were
the same as in Figure 2.32. 2 µL serum from these mice was measured as free glycerol
released from lipase digestion. ** and *** for p-value<0.01 and 0.001 by t-test in R.
n=5 or 6.
Lipoactive hormones such as epinephrine, norepinephrine, glucagon, thyrotropin, and
adrenocorticotropin release free fatty acids (Serum NEFA) into serum from lipolysis
in adipose tissues. And the liver can re-absorb almost 75% of the serum NEFA to re-
esterify them into triglyceride and release into serum as VLDL particle. Upon PPP2R5C
52
2. Results
knockdown, the steady state level of serum NEFA in random and fasting feeding regime
are not changed (Figure 2.40), which further indicates the increased lipid storage is
rather sourced from de novo lipogenesis in the liver. In refeeding, mice with PPP2R5C
knockdown even have significant increased serum NEFA. During refeeding, serum NEFA
could also be originated from the food intake. And it is possible the liver lipid synthesis
capacity has already reached its plateau and the NEFA is accumulated in the serum
to have a higher concentration in PPP2R5C knockdown mice than the control. This
postulation also fits with the fact that the liver triglyceride in refed condition stays at
very high level but there is still more triglyceride released into serum, which suggests























Figure 2.40.: Serum NEFA is decreased in refed. Mice were the same as in Figure 2.32. Lipid fraction
was extracted from liver by methanol-chloroform and triglyceride was measured as free
glycerol released from lipase digestion. 2 µL serum from these mice was measured for
NEFA. * for p-value<0.05 by t-test in R. n=5 or 6.
2.5. PPP2R5C negatively regulates VLDL secretion in
the liver
Given the fact that serum triglyceride was increased during fasting and refed, I performed
a more detailed analysis of serum lipid composition by FPLC (Fast Performance Liquid
Chromatography) fractionation of serum, in order to find which lipoprotein particle
was responsible for increased serum triglyceride. VLDL, IDL, LDL and HDL could
be nicely separated on a high resolution size-exclusion chromatography column. In
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Random group, mice after PPP2R5C KD has no diﬀerence in serum lipoprotein particle
profile (Total protein content (A280) in lipoprotein fractions is shown in Figure 2.41).
However, there is a significant increase in VLDL fraction (approximately 5-fold increase)
in Fasting and Refed group after PPP2R5C knockdown. In Fasting group, even there
is a slight increase in HDL intensity, the relative VLDL intensity normalized to HDL is






























Figure 2.41.: Increased VLDL fraction after PPP2R5C KD. Serum lipoprotein particles were ana-
lyzed by FPLC. 200 µL pooled serum from 5 or 6 mice in the same virus and feeding
group was subjected to FPLC separation on high-resolution size-exclusion chromatog-
raphy. FPLC profile was recorded as UV 280nm, which was the indicator for protein
concentration. Separated serum was collected in fractions of 0.5 mL. Mice were the
same as in Figure 2.32.
Concordantly, triglyceride distribution profile in serum is also agreed with increased
VLDL intensity (Figure 2.42). Although triglyceride concentrations in knockdown mice
from Refed group have higher background level, the background subtracted intensity
of VLDL triglyceride peak is distinctly higher than that for control mice in the same
feeding group. Quantification of VLDL peak apex and peak area both in FPLC and
triglyceride profile is shown in Figure 2.43. VLDL particles are lipoprotein particles
synthesized in the liver and secreted into the blood stream for transporting endogenous
triglyceride, cholesterol, phospholipids and cholesterol esters [107]. Comparing with
other lipoprotein particles, VLDL has the highest percentage of triglyceride, and could
explain the significant increase in serum triglyceride in the form of VLDL. The increased
















































































Figure 2.42.: Triglyceride concentration profile correlated with its FPLC profile. 160 µL from each
fraction was used to measure triglyceride concentration as free glycerol released from
lipase digestion.
FPLC Profile, Peak Apex FPLC Profile, Peak Area




































Figure 2.43.: Quantification of VLDL peak apex and area. Start and end point for each peak in
Figure 2.41 were manually selected by examining the emerging and vanishing time point
for each peak comparing with the background. Peak Apex and Area were calculated in




In agreement with the increased serum VLDL fraction, cholesterol level in this fraction
has also increased (Figure 2.44), although contributes a small share in total serum
cholesterol. The biggest cholesterol peak is from HDL, which is known to carry a high
percentage of cholesterol. And this minor contribution from VLDL cholesterol also
explain why there is no significant gain in the serum cholesterol level given the increased
cholesterol secretion from the liver (Figure 2.45). Liver cholesterol is probably passively
packaged into the VLDL particle together with the triglyceride and released into the
serum, due to the increased lipogenesis in the liver upon PPP2R5C KD. However, the
total serum cholesterol levels have not change (Figure 2.46) since the cholesterol from
VLDL is only a minor fraction comparing to the cholesterol from IDL and HDL peaks
(Figure 2.44), which are not changed dramatically upon PPP2R5C KD (Figure 2.41).
This data further validates the hypothesis that increased glucose uptake in the liver is
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Figure 2.44.: Cholesterol concentration profile in various lipoprotein particles. 40 µL from each frac-
tion was used to measure cholesterol concentration.
In summary, due to the increased lipogenesis derived from the increased glucose uptake
in the liver after PPP2R5C KD, VLDL secretion from the liver is also increased and con-
tributing to the anabolic storage of glucose in the liver. The increased glucose clearance
capacity of the liver after PPP2R5C KD enable the eﬃcient euglycemic control with
less insulin secretion from the pancreas in the postprandial phase or massive oral or
enteral glucose load (like GTT). The increased glucose absorbed by the liver is directed





























Figure 2.45.: Liver cholesterol is dropped in fasting and refed after PPP2R5C KD. Mice were the
same as in Figure 2.32. Lipid fraction was extracted from liver by methanol-chloroform
and cholesterol was directly measured. * and ** for p-value<0.05 and 0.01 by t-test in























Figure 2.46.: Serum cholesterol has no change after PPP2R5C KD in all feeding regimes. Mice were




glycogen deposition is partially driven by the increased liver glucose uptake, metabolite
or hormonal signaling from port vein, and partly by gluconeogenesis pathway [109]. In
PPP2R5C knockdown mice, the increased glucose uptake will probably also explain the
increased liver glycogen phenotype. Another possible anabolic change after increased
glucose uptake is storing glucose as triglyceride through de novo lipogenesis. The in-
creased glucose flux to the liver after PPP2R5C KD could potentially activate lipogenic
gene expression via multiple pathways. Glucose is considered as signaling metabolite
for activating glycolytic and lipogenic pathways [110]. In following sections, I will have
more data to show the direct and indirect link from PPP2R5C to glucose metabolism.
2.6. PPP2R5C’s substrates in metabolism control
2.6.1. PPP2R5C’s substrates include multiple metabolic regulators
PPP2R5C is a regulatory subunit of PP2A, thought to provide substrate specificity to
the phosphatase holoenzyme. However, given the phenotype I have observed from in
vitro and in vivo knockdown of PPP2R5C, it is not possible to make a direct link from
PP2A to the negative regulation of glycolysis and lipogenesis. There must be some inter-
mediate molecular links from PP2A to the regulation of glycolysis and lipogenesis, such
as glycolytic and lipogenic gene activation by some transcription factors and kinases. A
reasonable educational guess is that PPP2R5C regulates glycolytic and lipogenic gene
activation through de-phosphorylating metabolic regulators.
Therefore, I performed a proteomic approach to identify target substrates that bind
PPP2R5C. And potential substrates involved in metabolism control would provide a
clue to elucidate the mechanism of PPP2R5C’s negative regulation in glycolysis and
lipogenesis. However, phosphatase substrate discovery is diﬃcult. Beside occasionally
successes in finding phosphatase interacting substrates, there are few reports regarding
system-wide substrate identification for phosphatases, mostly protein tyrosine phos-
phatases [111, 112, 113]. In the case for protein tyrosine phosphatases, a substrate
trapping mutant competes with its endogenous counterpart for substrates. Due to its
structural simplicity (single subunit and verified catalytic dead mutant, usually a cys-
teine to serine mutation in catalytic active center), protein tyrosine phosphatase is much
easier for pulling down its binding substrates. For Serine/Threonine kinases, MAP ki-
nase phosphatase-1 is another success example of substrate trapping [114].
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Protein-protein interactions between phosphatases and substrates are notoriously tran-
sient and diﬃcult to detect via conventional methods, such as co-immunoprecipitation
and pull-down strategies. I have tested these conventional methods and abandoned
them for PPP2R5C substrate isolation due to the high background and no detectable
new band on SDS-PAGE gel. Here in the thesis project, I employed the BioID method
[115] to identify PPP2R5C interacting proteins, including its potential substrates. A
fusion between PPP2R5C and the biotin ligase BirA mutant (BirA*) was expressed
in Hepa 1-6 cells. The mutant biotin ligase (R118G) has been shown to be able to
generate reactive biotin (biotin-5’-AMP) and ligate biotin onto proteins in vitro [116,
117]. With the co-expression of substrate trapping mutant of PP2A catalytic subunit
C, fusion protein from PPP2R5C and BirA* led to in vivo biotinylation of PPP2R5C
interacting proteins, which can subsequently be isolated by collecting cellular lysates
and streptavidin pulldown (Figure 2.47).
By this way, these potential substrates with weak interactions with PPP2R5C would
have a higher chance to be identified by the Western blot or mass spectrometry with very
low background since it is possible to apply very stringent washing steps. BirA* was
fused to either the N-terminus or the C-terminus of PPP2R5C (Myc-BirA-PPP2R5C
and PPP2R5C-BirA-HA respectively), and Myc or HA-tagged BirA* alone was used as
a negative control. In addition, the catalytic dead mutation (D85N), which was known
to eliminate the phosphatase activity [118] by disrupting the Mg2+ binding in the active
center, was introduced into the catalytic subunit of PP2A (PP2CA). This design was the
first successful attempt to perform a substrate trapping assay for PP2A, and expected
to employ PP2A’s substrate-trapping mutation might extend the duration of interaction
between PP2A and its substrate proteins. Then there will be more in vivo biotinylation
on these substrates when the PP2A catalytic dead mutant is co-expressed.
In the BioID experiment, various known regulators of the liver metabolism were found
to be interacting with PPP2R5C, including AMPK b1, HIF1a, S6K1, STAT3 (Fig-
ure 2.48a). Comparing to either Myc-BirA* or BirA*-HA controls, HIF1a has increased
biotinylation, which is shown as stronger band after streptavidin pulldown and detection
with total antibodies for individuals. When co-expressed with the substrate trapping
mutant of PP2A catalytic subunit, the interaction between PPP2R5C and its substrates
is further increased. This proves the success of the substrate trapping mutant of PP2A,
which could potentially increase the binding duration of substrates to PPP2R5C con-
taining PP2A holoenzyme. For S6K1 and STAT3, similar results are also observed and
indicating their possibility of being PPP2R5C’s substrates. With AMPK’s various sub-
units tested in substrate trapping, including a, b1 and b2, only b1 subunit has been found
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Figure 2.47.: PPP2R5C containing PP2A holoenzyme substrate trapping and in vivo biotinylation
of its substrates.
to be a potential PP2A substrate. In contrast, no binding of PPP2R5C to SREBP-1,
or a panel of negative control proteins are detected, including HSP90, YAP, TSC1 and
RpL26 (Figure 2.48b).
2.6.2. AMPK is a PPP2R5C’s substrate involved in glucose uptake
The AMPK is a master regulator in energy homeostasis. It is a trimeric heteroge-
nous complex composed of a for catalytic activity, b for regulatory function, and g for
sensing AMP/ATP ratio. Given the interaction between AMPK b1 and PPP2R5C (Fig-
ure 2.48), there might also be some functional link between PP2A and AMPK. Indeed,
there were several reports showed the AMPK phosphorylation is negatively regulated by
PP2A [68, 69, 67]. However, which regulatory subunit in PP2A is responsible for AMPK
de-phosphorylation is still unknown. With PPP2R5C knockdown, the PPP2R5C con-
taining sub-pool of PP2A holoenzyme is reduced. AMPK activity is markedly increased
upon PPP2R5C knockdown with diﬀerent methods, either the adenovirus mediated
knockdown (Figure 2.49a) or an inducible shRNA stable cell line (Figure 2.49b). This
data clearly shows that PPP2R5C is at least one of the regulatory subunit of PP2A
involved in AMPK inhibition in liver originated cell lines. Accordingly, AMPK activity
change was further validated by the changes in its downstream eﬀectors’ activity such as
ACC1 phosphorylation, TBC1D1 phosphorylation. For ACC1 phosphorylation, it has
been well characterized as AMPK target and mediating AMPK’s inhibition on lipoge-
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(a) Western blot of PPP2R5C substrate (b) Negative controls of PPP2R5C substrate
trapping
Figure 2.48.: PPP2R5C’s substrates involved in metabolic control. (a) PPP2R5C interacting proteins
were validated by western blot. SREBP-1, Tubulin or Actin were used as non-interacting
controls. (b) AMPK b1 subunit and several other negative controls were used to validate
the specificity of PPP2R5C’s substrate trapping in an independent repeat experiment.
nesis [119, 120]. It is known that TBC1D1, the mouse homolog for human AS160, is
an upstream regulator for Glut1 translocation and phosphorylation at S700 of TBC1D1
promotes glucose uptake [121, 122]. This raises the possibility of AMPK activation after
PPP2R5C knockdown is mediating the increased glucose uptake phenotype (Figures 2.15
and 2.16).
2.6.3. HIF1a is a PPP2R5C’s substrate involved in glycolysis and
lipogenesis
The HIF1a is also known for controling glycolysis and lipogenesis in the liver [123, 124,
125, 126, 127]. The interaction between HIF1a and PPP2R5C, which is demonstrated
by the substrate trapping in Figure 2.48, indicates that HIF1a could also be one of
PPP2R5C’s potential substrates involved in metabolism control. However, there is no
phospho-specific antibody commercially available for HIF1a. Then I used Phos-tag R⃝ gel
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(a) AMPK activity increases upon PPP2R5C
KD
(b) Activity increase of AMPK and its down-
steam eﬀectors
Figure 2.49.: AMPK activity is up-regulated upon PPP2R5C knockdown. (a) AMPK activity is in-
creased after PPP2R5C knockdown by adenovirus packaged shR3 comparing to shRNC
(PPP2R5C KD vs Control KD). (b) Inducible shR3 and shR6 (PPP2R5C KD1 and
KD2) were used to examine the AMPK activity change in order to eliminate any virus-
mediated eﬀect in (a).
to evaluate the functional relevance of PPP2R5C knockdown on HIF1a’s phosphoryla-
tion status (Figure 2.50). Phos-tag R⃝ gel is made from an acrylamide analog containing
chemical group for binding phosphorylated ions specifically [128, 129, 130, 131, 132].
When protein is phosphorylated, its mobility in Phos-tag R⃝ gel will be retarded. As a
result, phosphorylated and non-phosphorylated proteins will be separated and protein
phosphorylation with unknown site could be possibly examined without phospho-specific
antibodies. The HIF1a has increased phosphorylated form upon PPP2R5C knockdown,
and this phosphorylation is also validated by CIP treatment (Figure 2.50). These data
suggest the PPP2R5C knockdown increases the phosphorylation of HIF1a.
In agreement with the phosphorylation increase upon PPP2R5C knockdown, HIF1a’s
transcriptional activity is also up-regulated after PPP2R5C knockdown (Figure 2.51)
in mouse primary hepatocytes. Four canonical down-stream targets of HIF1a are all
increased in mRNA level. Three of these four targets are involved in glycolysis, including
LDHa, HK2, and PKM2, could help to explain the increased glycolysis after PPP2R5C
knockdown. In addition, the activation of HIF1a in the mouse liver by hypoxia has
been shown to activate SREBP-1 consequently and promote lipid accumulation in the
liver [126]. Interaction between HIF1a and PPP2R5C provides a possible indirect link
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Figure 2.50.: HIF1a’s phosphorylation is increased after PPP2R5C KD. HIF1a’s phosphorylation sta-









































Figure 2.51.: HIF1a’s transcriptional activity is increased after PPP2R5C KD. Four HIF1a’s targets
were examined for its total mRNA level in mouse primary hepatocytes after PPP2R5C
KD.
from PPP2R5C KD to lipogenic gene activation, and elucidates the strong lipid storage
phenotype in mouse primary hepatocytes after PPP2R5C KD (Figure 2.17). The next
missing link in this hypothesis would be the SREBP-1 activation.
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2.6.4. Microarray analysis of PPP2R5C KD in mouse liver
In parallel with the substrate trapping experiment, I also performed the microarray
analysis on PPP2R5C knockdown cells and tissue samples to shed more light on the
mechanism behind the increased glycolysis and lipogenesis phenotype. Mouse primary
hepatocytes, Hepa 1-6 cells and mouse livers with or without PPP2R5C were submitted
for microarray analysis. For mouse liver samples, diﬀerent feeding groups was also
included. Diﬀerentially expressed gene list was generated based on 2-fold change cutoﬀ
for all feeding conditions and cell culture with PPP2R5C knockdown by the limma
package in R.
In order to find relevant transcription factors (TF) involved in the metabolic change
and further link these TFs to PPP2R5C substrates, I performed an enrichment analysis
for activated or inhibited TFs after PPP2R5C KD in mouse tissues or cell models. TF
enrichment analysis was done with an online web server of TFactS [133]. The TFactS
analysis is analyzing the diﬀerentially expressed genes with 2-fold cutoﬀ and finding the
most possible TFs for these genes based on published known target genes of various
TFs. The Transcription factor (TF) enrichment analysis from diﬀerentially expressed
genes in mouse liver with PPP2R5C KD has shown the increased SREBP-1 activity
after PPP2R5C KD both in cell and tissue samples (Tables 2.1 and B.1 to B.3).
During refeeding, both SREBP-1 and HIF1a were enriched based on their potential tar-
get gene activation (Table 2.1). The activated TF lists upon PPP2R5C KD in fasting
and random fed are shown in Supplementary Tables B.2 and B.3. The activated TF list
upon PPP2R5C KD in mouse primary hepatocyte and Hepa 1-6 is shown in Supplemen-
tary Table B.1. All these lists have SREBP-1 (gene name SREBF1) in the activation TF
list based on target gene expression. HIF1a, although only significant in FDR controlled
p-value, is also enriched in activated TF list. The activation of HIF1a and SREBP-1
further supports HIF1a as potential PPP2R5C’s substrate, and mediating the increased
lipogenesis phenotype after PPP2R5C KD, possibly through the downstream activation
of SREBP-1.
2.6.5. SREBP-1 is involved in lipogenesis phenotype
In Section 2.6.4, SREBP-1 is found to be activated upon PPP2R5C knockdown. Since
SREBP-1 is the master regulator in lipogenesis, and its over-expression in the liver cause
fatty liver [135]. Although SREBP-1 was not interacting with PPP2R5C in substrate
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Table 2.1.: Activated TFs in mouse liver upon
PPP2R5C KD during refed.
















a Adjusted p-value (false discovery rate) by Benjamini-Hochberg
method [134].
trapping experiment, SREBP-1 could still be involved in the lipogenesis phenotype af-
ter PPP2R5C KD in two possible ways. First, the decrease in the liver cholesterol
in fasting and refed group indicates that SREBP-1 activity increase could be the di-
rect result from liver cholesterol decrease due to the fact that the cholesterol and its
derivatives are endogenous molecules have been demonstrated to regulated SREBP-1
expression [136, 137]. Decreased cholesterol concentration will relieve the cholesterol’s
suppression on SREBP-1 activity. By this way, SREBP-1 is activated as a secondary ef-
fect from PPP2R5C KD. Secondly, SREBP-1 could also act as a downstream eﬀector in
HIF1a mediated lipogenesis [125]. The direct interaction between HIF1a and PPP2R5C,
together with the evidence of HIF1a phosphorylation change and transcriptional activa-
tion, obviously indicates that SREBP-1 activation could also be an outcome of HIF1a
activation. No matter the SREBP-1 activation is the primary or secondary consequences
after PPP2R5C KD, it is inevitable that the SREBP-1 activation is a downstream con-
sequence PPP2R5C KD, given that there is no interaction observed between PPP2R5C
and SREBP-1.
Indeed, the SREBP-1 activity is increased in the mouse liver upon PPP2R5C knockdown
when mice are subjected to fasting and refed (Figure 2.52). The SREBP-1 activation is
represented by increased SREBP-1 precursor protein level in Fasting and Refed group.
Since SREBP-1 can auto-activate itself, the increased precursor level clearly indicates
an SREBP-1 activation. Also, the mature form of SREBP-1, which is the direct mea-
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Figure 2.52.: SREBP-1 protein level is increased after PPP2R5C KD. Insulin signaling activity was
monitored by AKT and GSK3b phosphorylation.
surement of SREBP-1 activation, are also up-regulated both in Refed and Random
fed group. In addition, the insulin signaling activity, represented by the AKT and
GSK3b phosphorylation, is remained the same. This rules out the possibility that the
increased SREBP-1 activity is originated from the insulin signaling, a positive regulator
of SREBP-1 activity by increasing the SREBP-1 cleavage and maturation.
Additionally, qPCR analysis of several SREBP-1 target genes shows that the SREBP-1
transcriptional activity is also increased in mouse primary hepatocytes (Figure 2.53)
and the mouse liver (Figure 2.54) after PPP2R5C knockdown. Four canonical SREBP-
1 target genes involved in lipogenesis (DGAT2, GPAT1, ACLY, and SLC25A1) are all
significantly up-regulated after PPP2R5C knockdown in mouse primary hepatocytes
and mouse livers. Since SREBP-1 could auto-activate itself, increased SREBP-1 mRNA
level is also observed in the mouse liver after PPP2R5C knockdown during fasting and
refeeding (Figure 2.54). The transcriptional up-regulation of SREBP-1 itself is also fit


















































Figure 2.53.: SREBP-1 transcriptional activity is upregulated in PPP2R5C KD. Four SREBP-1’s
targets (DGAT2, GPAT1, ACLY, and SLC25A1 are all genes involved in lipogenesis)
were examined for its total mRNA level in mouse primary hepatocytes after PPP2R5C
KD.
lipogenesis in the mouse liver [127], even the mice are not under hypoxia. Both HIF1a
activity increase and cholesterol lowering after PPP2R5C knockdown would potentially
increase the SREBP-1 activity, which promotes the de novo lipogenesis.
In summary, PPP2R5C’s substrate trapping and microarray analysis after PPP2R5C
knockdown shed some light on how PPP2R5C could negatively regulate the glucose
uptake, glycolysis and lipogenesis. AMPK and HIF1a can be PPP2R5C’s direct down-
stream eﬀectors in metabolism control. In the branch of glucose uptake and glycolysis,
AMPK and HIFa could work in concert to promote the glucose absorption and gly-
colysis in hepatocytes. However, AMPK and HIFa seem to have an opposite function
in regulating lipogenesis. On one hand, HIF1a activation will promote lipogenesis via
SREBP-1. And on the other hand, AMPK activation after PPP2R5C KD could po-
tentially inhibit de novo lipogenesis via ACC1 phosphorylation [120] and inhibition on
SREBP-1 cleavage at high fat diet fed mouse [138]. The exact function of this opposite
control on lipogenesis is still unknown. However, a similar situation in signaling trans-







































































Figure 2.54.: SREBP-1 transcriptional activity is upregulated in mouse liver after PPP2R5C KD.




loop. This special design would allow rhythmical activation of downstream signaling or
avoiding over-shooting of the downstream activation signals [141, Chapter 4].
2.7. Human PPP2R5C in Type 2 Diabetes




































































































































Figure 2.55.: Human liver PPP2R5C mRNA levels correlate with T2D and GIR. PPP2R5C in healthy
control (Control) and type 2 diabetic patients (T2D) was normalized to 18S rRNA
level in liver, and shown as box-and-whisker plot (left panel). Human liver PPP2R5C
is also negatively correlates with covariate GIR (glucose infusion rate). *** for p-
value<0.001 by t-test in R for comparing Control to T2D. n=40 and 26 for Control
and T2D respectively. Cohort study and qPCR experiments were performed by Prof.
Matthias Blüher, Nora Klöting and Arne Dietrich in University of Leipzig, and analyzed
by Yong-Sheng Cheng.
In a cohort study of 76 liver samples from human, including 40 healthy donors and 26
type 2 diabetic patients (performed by my collaborator Prof. Matthias Blüher in Uni-
versity of Leipzig), human PPP2R5C total mRNA levels were checked by quantitative
PCR with 18S rRNA as the normalization control in Prof. Matthias Blüher’s lab. The
human liver PPP2R5C mRNA is significantly increased in type 2 diabetes (Figure 2.55).
The up-regulation of human PPP2R5C in type 2 diabetic patients is correlated with the
findings that almost all variants of mouse PPP2R5C are increased in the liver of db/db
mice, which is a mouse genetic model for type 2 diabetes (Figure 2.2). This up-regulation
in the human liver could be considered as a negative feedback of PPP2R5C transcription
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in order to curtail the lipid synthesis capacity of the liver, or a potential reason for in-
sulin resistance since PPP2R5C KD could improve insulin sensitivity. In type 2 diabetic
patients, majority of them will accumulate lipid in liver and develop fatty liver disease
in addition to type 2 diabetes. The PPP2R5C increase seems to have a protective role
for fatty liver development, however, result in liver’s less capacity in glucose clearance,










































Figure 2.56.: Human liver PPP2R5C mRNA levels correlates with the type and severity of obesity.
Healthy or type 2 diabetic persons are divided into lean, subcutaneous obese and visceral
obese. †† and † † † for p-value<0.01 and 0.001 by ANOVA analysis with comparison
between obesity groups. Cohort study and qPCR experiments were performed by Prof.
Matthias Blüher, Nora Klöting and Arne Dietrich in University of Leipzig, and analyzed
by Yong-Sheng Cheng.
Another interesting finding in this cohort study is that human liver PPP2R5C mRNA
levels negatively correlate with the Clamp Glucose Infusion Rate (GIR), which is a
measurement for glucose uptake rate in human (Figure 2.55). This piece of data also
agrees with the molecular function of PPP2R5C in the mouse liver. Knockdown of
PPP2R5C in the mouse liver increases glucose uptake rate after 6-hour fasting in mice
during the GTT test, which is demonstrated by the increased glucose tolerance after
PPP2R5C KD (Figure 2.28). This negative correlation between PPP2R5C and Clamp
GIR is independent of disease statuses. Both healthy donors and type 2 diabetic patients
have the negative correlation, which is shown in diﬀerent grey scales in scatter plot of
Figure 2.55 and correlation graph for all covariates (Figure 2.57).
Obesity has been shown to be a strong risk factor for type 2 diabetes [142]. The as-





































































Figure 2.57.: All covariates statistical significantly correlated with human liver PPP2R5C mRNA
level with Pearson method for correlation. The p-value cutoﬀ is 0.05 for significance of
the correlation in all subjects in the cohort. Correlation analysis was also performed
individually for healthy control and type 2 diabetic patient. All covariates are obesity
group (Group, including lean, sc, vis), visceral adipose tissue area (VATarea, cm2), gly-
cated haemoglobin (HbAc1, %), serum triglyceride (Triglyceride, mg/dL), blood glucose
after 2 hour OGTT (2hrs OGTT, mmol/L), fasting plasma glucose (FPG, mmol/L),
clamp glucose infusion rate (Clamp GIR, µmol/kg/min), serum cholesterol (Cholesterol,
mg/dL), LDL cholesterol (mg/dL), leptin (ng/mL), and IL6 (pmol/L). *, ** and ***
for p-value <0.05, 0.01 and 0.001 by correlation test in R by Pearson method. Cohort
study and qPCR experiments were performed by Prof. Matthias Blüher, Nora Klöting
and Arne Dietrich in University of Leipzig, and analyzed by Yong-Sheng Cheng.
Japanese descent, 60-80% of cases in those of European and African descent, and 100%
of cases in Pima Indians and Pacific Islanders [143]. Especially, the visceral obesity is
considered as a major culprit in developing insulin resistance [144, 145]. Apart from
the Clamp GIR, human liver PPP2R5C mRNA levels also vary among diﬀerent obe-
sity groups. All healthy controls and type 2 diabetic patients can be separated into
three groups based on the severity of obesity, from lean, to subcutaneous obesity (SC)
or visceral obesity (VIS). Increasing PPP2R5C over severity of obesity also indicates a
negative feedback control on PPP2R5C’s mRNA levels for reducing lipid synthesis and
VLDL secretion from the liver (Figure 2.56). Due to the lipid buﬀering function of the
liver, the secreted lipid in the form of VLDL will promote peripheral organs such as
adipose tissue and muscle to deposit more fat content.
Despite the correlation with Clamp GIR, PPP2R5C was also found to be correlated
with other 9 covariates in human (Figure 2.57). Among these covariates, the correlation
profile could be divided into three categories. The first group includes the visceral
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adipose tissue area, glycated hemoglobin, and serum triglyceride. In this group, the
positive correlations are present in all subjects (Total) and healthy sub-group (Control),
and the correlations are lost in type 2 diabetic patients. Visceral adipose tissue area is
another indicator of obese severity, and linearly correlates with the amount of visceral
adipose tissue. Thus the correlation pattern for visceral adipose tissue is similar to the
one for the obesity group covariate (Figure 2.56). Glycated hemoglobin is measurement
of average plasma glucose concentration over a prolonged time window, and considered
as a better marker for hyperglycemia. It is created by non-enzymatic glycation of
hemoglobin while exposed to the plasma glucose. This marker could represent 2–3 month
average plasma glucose level before the time point of measurement. Since the mouse
liver PPP2R5C KD can improve insulin sensitivity and then potentially lower blood
glucose in hyperglycemia, the positive correlation between human liver PPP2R5C and
glycated hemoglobin could be explained by the negative regulation of insulin sensitivity
of PPP2R5C in the liver. Serum triglyceride has been shown to be the strongest risk
factor for type 2 diabetes. And one of the major contribution for serum triglyceride is
the secreted VLDL from the liver [146]. The positive correlation between liver PPP2R5C
and serum triglyceride or glycated hemoglobin only in healthy control indicated the liver
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Figure 2.58.: Correlation profile discrepancy for fasting plasma glucose (FPG) and IL6. In FPG, the
positive correlation is due to group diﬀerence in healthy control and type 2 diabetic
patient (left panel). For IL6 (right panel), the correlation is across disease groups.
Cohort study and qPCR experiments were performed by Prof. Matthias Blüher, Nora
Klöting and Arne Dietrich in University of Leipzig, and analyzed by Yong-Sheng Cheng.
The second group includes the blood glucose after 2-hour OGTT and fasting plasma
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glucose. The positive correlations in this group come from the group diﬀerence between
healthy controls and type 2 diabetes. 2 hour OGTT glucose level above 7.8 mmol/L (140
mg/dL) indicates hyperglycemia [147]. Fasting plasma glucose (FPG) is normal within
the range of 4 to 5.5 mmol/L (70 to 99 mg/dL), while continual fasting levels of 5.5 to
7 mmol/L (101–125 mg/dL) indicates possible pre-diabetes, and FPG above 7 mmol/L
(126 mg/dL) indicates a high risk of diabetes [147]. The two positive correlations are
originated from their higher levels in type 2 diabetic patients, which results in a positive
correlation (shown in Figure 2.58 FPG vs PPP2R5C scatter plot).
The last group includes the serum cholesterol, LDL cholesterol, leptin, and IL6. The
positive correlations in this group are shown in all subjects (Total) and all sub-groups
(Control and T2D). The serum cholesterol and LDL cholesterol (so-called "Bad" choles-
terol) are normally higher in type 2 diabetic patients and will increase the risk for
cardiovascular disease. Leptin and IL6 have been also shown to related to type 2 dia-
betes and insulin resistance [148, 149]. Positive correlation between liver PPP2R5C and
these four covariates indicate PPP2R5C’s role in negatively regulating insulin sensitiv-
ity. The individual scatter plot for PPP2R5C vs IL6 are shown in Figure 2.58 as an
example for this group of covariates.
2.7.2. PPP2R5C’s misregulation in human adipose tissues
With another cohort study in human adipose tissues, PPP2R5C is also found to be
up-regulated in subcutaneous adipose tissues, but not in visceral adipose tissues from
type 2 diabetic patients (Figure 2.59, coordinated by Dr. Joan J Vendrell in Hospital
Universitari de Tarragona Joan XXIII, Spain). This cohort study is suggesting that a
similar metabolism control from PPP2R5C may also apply to other tissues besides liver.
These data fit nicely with the expression data from mice adipose tissues (Figure 2.3),



































Figure 2.59.: PPP2R5C mRNA levels in human adipose tissue from healthy donors and T2D patients.
Adipose PPP2R5C mRNA levels were analyzed by qPCR with cyclophilin 1A (PPIA)
as the normalization control. Cohort study and qPCR experiments were performed by
Sonia Fernandez-Veledo (Hospital Universitari de Tarragona Joan XXIII) and Antonio
Zorzano (IRB Barcelona), and analyzed by Yong-Sheng Cheng. t-test for Control and
T2D was done in R.
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In this thesis project, the tissue-specific function of PPP2R5C has been shown at the
first time by the hepatocyte-specific knockdown of PPP2R5C both in vitro and in vivo.
From the Expression Altas database at EBI, although the liver is not the organ having
the highest PPP2R5C expression comparing to the heart, brain, testis and thymus, in
vivo liver knockdown of PPP2R5C changes the mouse metabolism profoundly. The pro-
found change in metabolism, from the glucose uptake to lipogenesis, is likely resulting
from multiple actions of PPP2R5C on its substrates. And the substrate multiplicity in
metabolism control makes PPP2R5C a novel and interesting drug target in developing
pharmaceuticals for controlling hyperglycemia and hyperinsulinemia in the future. Fur-
ther characterization of the gene regulation in PPP2R5C is also an interesting topic open
for new mechanism in etiology of diabetes, especially with the fact that the PPP2R5C
is misregulated in the type 2 diabetes and has predicted HNF1a and NF-kB sites on its
promoter. Both HNF1a and chronic inflammation has been linked to the development
of diabetes [89, 150].
3.1. PPP2R5C in liver metabolism
PPP2R5C, a PP2A regulatory subunit, is identified as a metabolism modulator in hepa-
tocytes. Reduced PPP2R5C expression leads to the increased glucose uptake, glycolysis
and de novo lipogenesis in in vitro cultivated hepatocytes and mouse hepatoma cell
line. These phenotypes are recapitulated in vivo whereby liver-specific knockdown of
PPP2R5C in mice results in the improved glucose tolerance and insulin sensitivity, but
elevated circulating VLDL levels (Figure 3.1). The phenotypes presented in this the-
sis were obtained by knocking down PPP2R5C with multiple independent miRNA or
shRNA sequences (See Table A.6) and diﬀerent shRNA/miRNA expression systems,
including AV, AAV and piggyBac inducible system. For instance, the increased glucose
uptake was observed in cell culture using two independent shRNAs (Figure 2.15) and a
third independent target sequence in vivo (Figure 2.28). This excludes the possibility
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that the phenotypes could arise from possible oﬀ-target eﬀects or virus-mediated eﬀects.
Therefore, PPP2R5C is a fine-tuning regulator for adjusting the balance liver has to
make, which is the equilibrium between preventing circulating glucose levels from be-
coming too elevated in the postprandial phase (alternatively, high oral or enteral glucose
load, such as that in GTT), and yet not flooding the circulatory system with lipids. With
higher expression of PPP2R5C in the liver, mice would end with less glucose uptake and
eventually less lipid secretion to the circulation. However, the glucose uptake in other
tissues, such as muscle and adipose tissues, need cooperatively increase their glucose ab-
sorption in order to control the mild hyperglycemia in the postprandial phase or other
conditions with massive glucose load. With less expression of PPP2R5C in the liver,
liver will relieve the glucose uptake burden for other tissues, such as muscle and adipose
tissues, but will release more lipid into circulation and have long-term risk for cardiovas-
cular diseases in the expense of better insulin sensitivity and improved glucose tolerance.
These scenarios could make fine-tune of the PPP2R5C expression level a tough choice
for mouse liver during evolution. Mice have to evolve an appropriate level of PPP2R5C
expression to have a balanced glucose uptake and lipid secretion in the liver.
Interestingly, PPP2R5C liver-specific knockdown mice have reduced levels of serum
insulin (Figure 2.26) but normal levels of circulating glucose (Figure 2.25) under various
feeding conditions. One possible reason for the reduced insulin level can be that the
pancreas, which is the central control unit for the euglycemia in the body, is not aﬀected
in PPP2R5C liver-specific KD mice. Consequently, the pancreas is still remaining its
blood glucose controlling function normally to maintain a proper blood glucose level,
reducing its insulin secretion to compensate for the elevated glucose clearance by the
liver.
Due to the increased VLDL secretion in fasting and refed conditions, steady-state triglyc-
eride level in the liver shows a decrease in fasting and no further increase in refed, unlike
the increased triglyceride during ad libitum feeding. Given the continuous consumption
of triglyceride from circulating VLDL by adipose tissues, muscle and other peripheral
tissues during fasting, the overall triglyceride production in the liver could still be in-
creased. This hypothesis could be further resolved by in vivo tracer study to clarify how
much isotope-labelled glucose is converted into the liver and serum triglyceride. During
refed, the combined triglyceride from liver and serum are increased upon PPP2R5C
KD, and the liver triglyceride was increasing faster than control during re-accumulating
triglyceride after fasting (Figure 3.1). The evidence demonstrated the general func-
tion of PPP2R5C in inhibiting lipogenesis during all feeding regimes (at least for ad
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Figure 3.1.: Whole organismal control model for PPP2R5C in glucose and lipid homeostasis in liver.
Upon PPP2R5C knockdown in liver, glucose uptake is increased in the postprandial
phase or high glucose load during GTT. Glucose in the liver is quickly converted to
glucose-6-phosphate in order to stay in the liver. The absorbed glucose is further stored
either as glycogen or triglyceride. Increased triglyceride storage triggers VLDL secretion
and results in passively lowering liver cholesterol. During fasting, the higher rate of
VLDL secretion could cause the decreased liver triglyceride, while increased triglyceride
synthesis rate during refeeding balances triglyceride production and secretion from liver
and results in no net change in liver steady-state triglyceride level.
libitum feeding and refed). Another consequence after the increased VLDL secretion
is that liver cholesterol levels drop significantly during fasting and refed (Figure 2.45).
The decreased level of cholesterol could also contribute the SREBP-1 activation in the
liver (Figures 2.52 and 2.54), since cholesterol is an endogenous inhibitor for SREBP-1
activation [137].
In short term, reducing PPP2R5C levels in liver seems to have a beneficial role in whole
organismal level (Figure 3.1). The liver becomes more capable of glucose deposition
in the postprandial phase, and reducing the relative glucose burden on other insulin-
sensitive glucose uptake tissues such as adipose tissues and muscle. This feature could be
employed in controlling hyperglycemia in metabolic syndromes. The long-term reduction
in liver PPP2R5C, which has been shown in knockout mice for PPP2R5C [79], results
in the obesity in mice. Although the reason for the obesity in whole body knockout
mice can not be solely attributed to the liver, the increased VLDL secretion from liver-
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specific knockdown mice raises the risk of developing obesity and cardiovascular diseases.
However, the long term consequence of PPP2R5C manipulation still need to be carefully
investigated.
3.2. PPP2R5C substrates
Although the phenotypes after PPP2R5C knockdown, the increased glycolysis and lipo-
genesis, are quite specific both in cell culture and in vivo mouse experiment. However,
they are still could be a result from the eﬀects of PPP2R5C on multiple downstream sub-
strates. Thus, it will be diﬃcult or even impossible to pin down single one PPP2R5C’s
substrate as the main mechanism for explaining most of the eﬀects of PPP2R5C KD.
Here 4 protein complexes were identified as PPP2R5C interacting partners including
AMPK, HIF1a, STAT3 and S6K. I tested whether the phosphorylation of these pro-
teins increases upon PPP2R5C knockdown, which would be the expected result from a
PPP2R5C target.
For STAT3, I used the phospho-specific antibody for S727 of STAT3 to check the phos-
phorylation change upon PPP2R5C KD, and there was no change in two independent
inducible shRNA mediated KD (data not shown). Again, I used the Phos-tag R⃝ gel to
test STAT3’s motility shift due to increased phosphorylation in an approach similar to
what I did for HIF1a (Figure 2.50). Although there were no obvious changes in STAT3’s
motility, an important caveat of Phos-tag R⃝ from my experience is that Phos-tag R⃝ gels
could only resolve phosphorylations on roughly one third of the proteins I have tested
and know to be phosphorylated. There is still possibility that STAT3 is diﬀerentially
phosphorylated after PPP2R5C KD.
For S6K, I also checked the phosphorylation of Thr389 by using commercially available
phospho-specific antibody. It was not up-regulated upon PPP2R5C knockdown. Also, I
evaluated the S6K phosphorylation on other sites by Phos-tag R⃝ gel, and the result was
hard to explain the existence of band shifting due to multiple bands for S6K. The mul-
tiple bands separated on Phos-tag R⃝ gel would potentially mask some changes. For this
reason, S6K branch was not explored in depth, although this does not exclude the possi-
bility of PPP2R5C’s regulation on S6K’s other site phosphorylation. For these reasons,
I focused more on AMPK and HIF1a for deciphering PPP2R5C’s role in metabolism
control.
For AMPK and HIF1a, I evaluated both the phosphorylation and activity of them upon
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PPP2R5C knockdown. Both AMPK and HIF1a are known to increase the glycolytic
flux in response to stress conditions, either imbalanced ATP/ADP ratio or impaired
mitochondrial function [151, 152]. Therefore AMPK and HIF1a tend to work in concert
to promote the glucose uptake and glycolysis upon PPP2R5C knockdown (Figure 3.2).
For PPP2R5C’s control in the glucose uptake and glycolysis branch, at least in Hepa 1-6
cells and primary hepatocytes, AMPK activity and its downstream eﬀector in glucose
uptake–TBC1D1 phosphorylation are shown to be increased. TBC1D1 phosphorylation
is known to be a critical mediator in glucose uptake stimulation followed from AMPK
activation, and its phosphorylation at Ser700 and Ser660 sites are bona fide AMPK
target [121]. Both glut1 and glut4 translocation have been shown to be regulated by
TBC1D1 phosphorylation. However, glut2 is the highest expressed glucose transporter
in hepatocytes, while glut1 or glut4 is lowly expressed, and glut1 is only expressed in
sinusoidal membrane of hepatocytes with its protein restricted to hepatocytes proximal
to the hepatic port venule [153]. The expression pattern of glut1 in the liver indicates
TBC1D1 mediated glut1 translocation could potentially play a role in glucose uptake at
port vein where massive glucose load is encountered in the postprandial phase or enteral
glucose overload.
Indeed, the in vivo function of AMPK has also been carefully investigated in the mouse
liver, which is the increased liver AMPK activity leading to the decreased blood glucose
and fatty liver [154]. The reduced liver AMPK activity leading to a glucose intolerance
[155], in agreement with the potentially increased AMPK activity upon PPP2R5C KD.
However, the activation of AMPK phosphorylation at Thr172 has not been observed in
the mouse liver sample after PPP2R5C KD. Only ACC1 phosphorylation increase has
been observed, yet with increased total ACC1 (data not shown). Although the pheno-
type of increased glucose uptake in vivo is still fit with potentially activated AMPK, it
is inevitable that other mechanisms downstream of PPP2R5C are also contributing to
glucose uptake phenotype.
I have also evaluated the HIF1a phosphorylation by Phos-tag R⃝ gel since there was no
commercially available phospho-specific antibody for HIF1a, and found its phosphory-
lation is increased upon PPP2R5C knockdown in Hepa 1-6 cell model. Concordantly,
the HIF1a transcriptional activity is also up-regulated in mouse primary hepatocytes.
These data indicate the functional consequence of HIF1a phosphorylation increase upon
PPP2R5C KD could be the transcriptional activation of HIF1a. Further study would
be needed to identify the phosphorylation site after PPP2R5C KD.
The functional relevance of HIF1a is still less clear, given that the mice I was studying
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Figure 3.2.: Signaling model of PPP2R5C in glycolysis and lipogenesis in cell. PPP2R5C containing
PP2A complex inhibits AMPK and HIF1a activity via de-phosphorylation. Although
AMPK has been shown to be a negative regulator for SREBP-1 [138], SREBP-1 could
still be activated by the upstream HIF1a activation [126] and potentially lower liver
cholesterol in PPP2R5C knockdown at long term. Activated AMPK [122, 156, 121] and
HIF1a [123, 152] could both contribute to the increased glucose uptake and glycolysis in
a cell-autonomous way. Even increased glycolysis itself could also contribute to de novo
lipogenesis [23, 110].
were housed under normoxia. Mice with liver-specific knockout of HIF1b developed di-
abetic phenotypes [127], however HIF1b binds also other partners besides HIF1a. The
hepatocyte-specific knockout of HIF1a shows impaired glucose tolerance in Oral GTT
testing [123], which is fit nicely with the improved glucose tolerance in PPP2R5C KD
mice with potential HIF1a activation. In cell culture experiments with Hepa 1-6 cells
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or primary hepatocytes, also conducted under normoxia, HIF1a is indeed functionally
relevant because I can detect the HIF1a protein by Western blot (Figures 2.48 and 2.50)
and see the induction of HIF1a target genes upon PPP2R5C knockdown (Figure 2.51).
HIF1a is known to be frequently up-regulated and functionally relevant to cancers,
therefore HIF1a is likely to be a relevant downstream PPP2R5C target in this patho-
physiological context. Finally, the SREBP-1 activation was observed in PPP2R5C KD
livers, which likely accounts for their increased de novo lipogenesis. SREBP-1 can be
activated downstream of HIF1a but additional mechanisms are likely to link PPP2R5C
to SREBP-1 activation [157]. The lower cholesterol level in PPP2R5C KD liver could
also explain the SREBP-1 activation.
Besides these substrates identified in this project, other known interaction partners of
PPP2R5C could also possibly contribute to the phenotypes after PPP2R5C KD, such
as SERCA2a or SERCA3a identified in a proteomic search of PPP2R5C interaction
proteins [81]. In mammalian system, loss of the endogenous regulator of SERCA2a,
sarcolipin, results in mice predisposed to diet-induced obesity [158]. Similarly, loss of
Drosophilla SERCA results fat accumulation in fat body of fly [83]. The conserved
function of SERCA family in lipid accumulation during evolution could be another
plausible mechanism for increased lipogenesis phenotype upon PPP2R5C KD in hep-
atocytes. However, the phosphorylation of SERCA or ER calcium2+ level has to be
examined in PPP2R5C KD cells in order to find the connection between PPP2R5C KD
and SERCA-mediated signaling on lipogenesis.
3.3. PPP2R5C’s metabolic control in cancer cells
PPP2R5C has been linked to the cancer development. One mechanism in human appears
to be the dephosphorylation of p53 on Thr55 [9, 11, 10]. However, this mechanism is not
possible in the mouse due to the missing Thr55 in mouse p53. The results described here
suggest an alternative mechanism for PPP2R5C’s down-regulation in controlling cancer
cell growth and proliferation by increasing the cancer cell glucose uptake, glycolytic
rate, and lipid biosynthesis–all of which are metabolic hallmarks for cancer cells. This
also fits with the tumor suppressor function of PPP2R5C, which is inhibiting the cell
proliferation in cancer cells through reprogramming metabolism toward anabolic growth.
Therefore, it will be interesting to study in the future whether these metabolic eﬀects
might be contributing towards the tumor suppressive properties of PPP2R5C in other
tumor types besides hepatoma.
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As potential PPP2R5C substrate, HIF1a has been frequently stabilized and activated in
solid tumor, and becomes the driving force for metabolic reprogramming toward "War-
burg" eﬀect by increasing glucose uptake and glycolysis [152]. PPP2R5C’s regulation on
HIF1a provide a novel pathway to modulate HIF1a activity via phosphatase. Addition-
ally, with recent advances in genome editing technology, it is now possible to specifically
activate PPP2R5C expression with the help from CRISPR/Cas9 mediated genome-loci
specific targeting and gene activation [159, 160]. Local activation of PPP2R5C in tumor
cells would be a new perspective on drug development for cancer, turning PP2A a tumor
suppressor as new druggable target for modulating HIF1a and other signaling pathways
in cancer cells.
3.4. PPP2R5C in human metabolic diseases
From PPPR5C knockdown experiments, it has been clearly shown that PPP2R5C ex-
pression in the liver inhibits the glucose uptake and reduces the insulin sensitivity.
Astoundingly, PPP2R5C expression level in human liver also correlates with insulin re-
sistance. Type 2 diabetic patients have significantly elevated PPP2R5C liver expression
levels compared to controls (Figure 2.55). In fact, even within the control population
PPP2R5C expression correlates with reduced insulin sensitivity (Figure 2.55), raising the
hypothesis for future studies that increased PPP2R5C expression might play a causative
role in insulin resistance.
In type 1 or 2 diabetes, postprandial hyperglycemia and impaired hepatic glycogen
storage are the two most prominent characteristics [26]. Targeting postprandial glucose
(PPG) level has also become a major interest in drug development for diabetes [161].
In fact, 2-hour GTT is still considered to be the gold standard for diagnosis of diabetes.
And PPG has also been shown as frequently the earliest abnormality of type 2 diabetes,
and an independent risk for cardiovascular diseases [162]. In this thesis project, liver-
specific knockdown of PPP2R5C has been shown to induce profound metabolic changes,
including increased insulin sensitivity without aﬀect fasting blood glucose level, increased
glucose uptake in GTT and consequently increased glycogen and triglyceride storage
in the liver. PPP2R5C liver-specific knockdown has provided a new drug target for
controlling PPG via multiple possible pathways.
Either via liver-specific siRNA mediated knockdown or interrupting interactions between
PPP2R5C and PP2A holoenzyme (A and C subunits), PPP2R5C’s substrates can be
specifically modulated in term of increasing their phosphorylation levels. Liver-specific
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siRNA delivery has been quite successful in recent studies [163, 164]. In the future,
with more eﬃcient and specific siRNA delivery system development, it is reasonable
to test the clinical possibility of the liver-specific knockdown of PPP2R5C to improve
postprandial hyperglycemia in diabetic patients. Currently, liver-specific knockdown of
PPP2R5C in the mouse model of type 2 diabetes (db/db mice) is ongoing. With the
recent development in phosphatase-based drug development [43], it is also plausible to
develop activators or inhibitors for PP2A. Inhibitors, which could disrupt PPP2R5C’s
interaction with PP2A holoenzyme (A and C subunits) or specific substrates like AMPK
or HIF1a, can be employed to target the liver and mimic the liver-specific knockdown




4.1.1. DNA digestion by restriction enzymes
All plasmids and PCR products were digested by restriction enzymes from Fermentas
(Now part of Thermo Fisher Scientific). DNA was digested with restriction enzymes in
1×FastDigest R⃝ buﬀer for 2 hrs in 37◦C.
4.1.2. Polymerase chain reaction (PCR)





Forward Primer (100µM) 0.2
Reverse Primer (100µM) 0.2
dNTP (10mM) 2
10×Standard Taq buﬀer 5
Taq DNA polymerase 1
For each reaction, bacterial clone was touched by pipette tip and washed in 10 µL sterile





Step Temperature Time Cycles




Final 72◦C 5′ 1
For cloning Genomic DNA fragment from mouse liver gDNA, Expand R⃝ Long Range
DNA polymerase from Roche was used and condition was following:
Recipes:
Components 1×Master Mix(µL)
H2O fill up to 50 µL
Template (gDNA,10–500ng/µL) 0.5
Forward Primer (100µM) 0.3
Reverse Primer (100µM) 0.3
dNTP (10mM) 2.5
5×Expand long rang buﬀer 10
DMSO 0,1,2 or 3
Expand long range enzyme mix 0.7
PCR running condition:
Step Temperature Time Cycles






Elongation 68◦C 60′′/kb + 20′′/cycle
Final 68◦C 7′ 1






H2O fill up to 50 µL
Template (cDNA) 0.5
Forward Primer (100µM) 1
Reverse Primer (100µM) 1
dNTP (10mM) 2
10×Hotstart R⃝ Taq buﬀer 5
Hotstart R⃝ Taq DNA polymerase 0.5
PCR running condition:
Step Temperature Time Cycles




Final 72◦C 5′ 1
4.1.3. Agarose gel electrophoresis
Agarose gel electrophoresis was employed to separate and purify DNA products from
PCR, plasmid digestion, etc.. Normally, 0.7–1.5% ultrapure agarose gel was prepared in
1×TAE by microwave mediated boiling. For separating ds/ss oligos, 4% agarose gel was
prepared with occasional shaking and mixing during boiling to help dissolving in TAE.
DNA samples were mixed with 1/10 volume of 10×GelRed dye stock solution. Running
condition was 95–125V (constant voltage) depend on the size of the electrophoresis
chamber used. Running time was 45 min as standard, and varied depending on the
separation resolution needed (ie. separating size diﬀerence of 100–200 bp need more
running time).
4.1.4. Agarose gel purification
The cut agarose gel was submitted to purification using NucleoSpin R⃝ Gel and PCR





DNA ligation was done by mixing insert and linearized vector in 3:1 ratio (molarity
ratio, 10:1 for blunt end) with following recipes.
Recipes:
Components 10 µL reaction
H2O fill up to 10 µL
Insert varies for insert size
Vector 1
10×T4 DNA ligase buﬀer(NEB) 1
T4 DNA ligase(NEB) 0.5
Ligation was usually done within 20 min at room temperature. For the ligation between
dsDNA oligo and vector, ligation could also done at 16◦C or 4◦C overnight for better
ligation eﬃciency.
4.1.6. Transformation of E. coli
XL1 Blue competent cell was used for most gDNA, cDNA and oligo cloning. For cloning
miRNA or shRNA, SURE 2 competent cell from Agilent Technologies and TOP10 from
Life Technologies were used respectively. 1–4 µL ligation product was used for transfor-
mation and mixed with 50–100 µL competent cell suspension, then incubated on ice for
45 minute. Heat shock was done at 42◦C for 30–45 seconds. Following incubation with
1 ml more LB medium at 37◦C was only needed for kanamycin resistant plasmid and
occasionally for ampicillin resistance plasmid if transformation eﬃciency is very low.
4.1.7. Bacteria cultivation and plasmid purification
Transformed bacteria with plasmid was incubated at 37◦C and shake at 230 rpm
overnight in 2–5 ml LB medium or other special medium (NZY+ medium for SURE
2). Plasmid was isolated and purified with NucleoSpin R⃝ Plasmid from Macherey-Nagel.
All procedures were followed according to the manufacture’s standard protocols. All
purified plasmids were stored at -20◦C. If sequencing is needed, All plasmids were sent
to GATC Biotech for sequencing.
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4.1.8. Cloning and selection of shRNA or miRNA candidates
shRNAs or miRNAs against common region in all PPP2R5C transcripts were designed
on Invitrogen’s BLOCK-iTTM RNAi designer website (BLOCK–iTTM RNAi Designer).
3 independent shRNA and 14 miRNA were selected based on their top positions on
the rank list. Oligos for these shRNAs and miRNAs were synthesized from Sigma and
cloned into Invitrogen’s BLOCK-iTTM adenovirus and adeno-associated virus system
especially according to manufacturer’s instruction. Knockdown eﬃciency was evaluated
by co-expression of miRNA/shRNA with HA-tagged Variant 2 of PPP2R5C and checked
by western blot.
4.1.9. Cloning miR30-based shRNA for the inducible piggyBac
shRNA system
miR30-based shRNA was designed either using shRNA3 sequence designed at Invit-
rogen’s RNAi website or new sequences predicted from Gregory Hannon’s laboratory
website for shRNA design (RNAi Central shRNA). 3 independent shRNAs were syn-
thesis and cloned into piggyBac transposase system with inducible shRNA expression
(System Biosciences, PBQMSH812A-1).
4.2. Gene expression analysis
4.2.1. Tissue pulverization
Frozen tissue was transferred into liquid nitrogen pre-cooled adapter sets with steal
beads. The tissue was pulverized by TissueLyser IITM(Qiagen) for 1 min and at a
frequency of 30 Hz (repeat if tissue was not homogeneous powder). Transfer pulverized
powder into original tubes for these tissue samples.
4.2.2. RNA isolation from tissue sample
~50 mg of frozen tissue were weighted and transferred into a 2 ml RNase/DNase/Protease-
free reaction tube containing 1 ml of QiazolTM Lysis reagent and a stainless steel bead.
The samples were homogenized using the TissueLyser IITM (Qiagen) for 1 min and at a
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frequency of 30 Hz. Lysate was transferred into a new 1.5 ml RNase/DNase free tube,
and 200 µL chloroform was added into each tube. The mixture was further vortexed
for 15 seconds at room temperature and then incubated under the hood for 15 minutes.
To separate the RNA containing water phase, sample was centrifuged at 14, 000 rpm
for 15 minutes at 4◦C. Then 400 µL upper water phase was taken out and mixed with
equal volume of isopropanol in a new tube, then another 14, 000 rpm 15 minute cen-
trifugation at 4◦C was applied to separate the RNA pellet. After washing with 70%
ethanol twice, RNA pellet was dried at room temperature till no visible solution, and
then re-solubilized in 50 µL water. To increase the solubility, the RNA solution was
incubated at 60◦C for 10 min. The samples were stored at -80◦C until further use.
4.2.3. RNA isolation from cell sample
1 ml TrizolTM Lysis reagent was directly applied onto cell in 6-well plate after removal
of medium. Plate was then shaken on head-to-tail rotator for 2 min to allow complete
lysis of the cell till no visible debris left. Then the lysate was transferred into 1.5 ml
tube and 200 µL chloroform was added and mixed by vortexing for 15 seconds. RNA
containing water phase was separated by centrifugation at 14, 000 rpm for 15 minutes
at 4◦C. Then 400 µL upper water phase was taken out and mixed with equal volume of
isopropanol in a new tube, then another 14, 000 rpm 15 minute centrifugation at 4◦C
was applied to separate the RNA pellet. After washing with 70% ethanol twice, RNA
pellet was dried at room temperature till no visible solution, and then re-solubilized in
50 µL water. To increase the solubility, the RNA solution was incubated at 60◦C for 10
min. The samples were stored at -80◦C until further use.
4.2.4. cDNA synthesis
2–5 µL (depend on the concentration, make sure about 2 µg total RNA) RNA sample
was used to synthesize cDNA from it. At first, RNA mix was prepared as following and
heated at 65◦C for 5 min:
Components 14.5 µL in total
H2O 10.5





Then add 5.5 µL RT mix from following recipes, and mix well.




Then sample was put on PCR machine from Bio-Rad (DNAEngine) at 50◦C for 50
minutes and then inactivate enzyme in the reaction by heated sample up to 85◦C for 5
minutes. After these steps, cDNA sample was stored at -20◦C.
4.2.5. Quantitative PCR (qPCR) analysis
cDNA sample prepared as above was diluted in 1:60 in RNase/DNase/Protease-free
water. Then 4 µL of diluted cDNA as template for qPCR analysis. Working master
mix for qPCR was made from 5 µL 2×Maxima SYBR Green/ROX qPCR Master Mix
(Fermentas), and 1 µL oligo mix (2.5 µM each primer). The PCR reaction mix was
transferred to a MicroAmpTM Optical 96-well reaction plate (Applied Biosystems). All
reactions were performed in technical duplicates. Quantitative PCR was performed
using a StepOne Real Time PCR System (Applied Biosystems, now part of Thermo
Fisher Scientific). Gene expression levels were calculated by ∆∆Ct method.
4.2.6. Microarray analysis of mouse tissue and cell sample
Expression profile analysis by microarray was done for RNA sample from Hepatoma
cell line Hepa 1-6, primary mouse hepatocytes and mouse liver tissues with infection
by adenovirus packaged with control shRNA or shRNA targeting common region of all
mouse PPP2R5C splicing isoforms at MOI (Multiplicity of Infection) of 100. RNA
was isolated as protocol in Section 4.2.3 and send to DKFZ’s in-house Genomics & Pro-
teomics Core Facility for microarray analysis. RNA sample was analyzed on Bioanalyzer
(Agilent Technologies) for quality control and then submitted for cDNA synthesis and
microarray analysis using MouseWG-6 v2.0 Expression BeadChip Kit from Illumina Inc.
The raw data from the core facility was sent back and further processed and analyzed
on DKFZ’s in-house Chipster server [165]. Alternatively, raw data was processed in R




4.3.1. Cell culture for Hepa 1-6, HEK293T, HEK293A, Hela Cells
All cell lines were maintained and propagated in Dulbecco’s Modified Eagle Medium with
4.5 g/L glucose (DMEM), 10% fetal calf serum (FCS) and 1×penicillin/streptomycin
(100 IU and 100 µg/mL). HEK293A and HEK293T cells also required 1×Non-Essential
Amino Acids (NEAA). Cell was split in 1:10 twice per week. Experiments involving
eukaryotic cells were performed under sterile conditions. Media and reagents were pre-
heated to 37◦C prior to use. All cells were cultivated at 37◦C, 5% CO2 and 95% humidity
in 96-well, 24-well, 12-well, 6-well, 10 cm or 15 cm cell culture dishes.
4.3.2. Transfection assay
For the transfection plasmid into cells, Eﬀectene R⃝ Transfection Reagent from Qiagen
was used according to standard protocols provided in kit’s instruction. Medium with
transfection reagent was exchanged with fresh medium after overnight incubation. Ad-
ditional 1-2 day was needed for proper expression of exogenous genes.
4.3.3. Mouse primary hepatocyte cultivation
For cultivated mouse primary hepatocytes, two diﬀerent sources of them were kindly
provided by Prof. Herzig’s and Prof. Klingmüller’s lab especially. These two sources
of hepatocytes were prepared in each lab with the same protocol of isolation. However,
hepatocytes from Prof. Klingmüller’s lab were also counted for living cell by trypan blue
staining and exactly 1 million cell were seeded on 6-well plate. Here only the protocol
from Prof. Herzig’s lab is described for simplicity.
Mouse primary hepatocytes were isolated and in vitro cultivated as standard procedure
in Prof. Herzig’s lab [166]. Male 8–12 week old C57Bl/6J mice were housed for 1 week
and then anesthetized by intra-peritoneal injection of 5 mg 10% ketamine hydrochlo-
ride/100 mg body weight and 1 mg 2% xylazine hydrochloride/100 mg body weight.
When there was no response from pressing mouse foot, it was then allowed to open the
abdominal cavity. The liver was then perfused with HANKS I buﬀer via the portal vein
for 5 min at 37◦C and subsequently with HANKS II buﬀer for 5–7 min until complete
disruption of the liver structure is visible (color change from red to pale). Then the liver
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was cut out and the liver capsule was removed and washed gently in adhesion buﬀer
(recipe in Table A.4) until no visible cell was left attached onto the capsule. Then the
liver cell suspension was filtered through a 100 µm mesh fitted into 50 mL Falcon tube
(BD Biosciences). Hepatocytes were washed twice and gently collected by centrifugation
at 37.5×g at room temperature. Cell suspension from one mice was equally distributed
in collagen I-coated 6-well plates (roughly 1 million cell for complete coverage) without
checking the cell viability by trypan blue staining. Hepatocytes were infected with re-
combinant adenoviruses (MOI = 10, 100 or 200) 4 hours after seeding and harvested
for gene expression analysis or submitted for Triglyceride, free fatty acid, glucose, and
lactate measurement after 48 or 72 hours later.
4.3.4. PP2A substrate trapping in Hepa 1-6
Protein-protein interaction mapping by biotinylation [115] was adapted to discover new
substrate of PP2A holoenzyme with PPP2R5C as regulatory B′ subunit. In order to
stabilizing interaction between substrates and PP2A, a phosphatase dead mutant of C
catalytic subunit of PP2A was also co-expressed together with promiscuous biotin ligase
tagged PPP2R5C Variant 1. The mechanics behind this method design is call substrate
trapping. It has been successfully used to find several protein phosphatases’ substates
[111, 112, 113]. 2 µg of each plasmid was transfected into Hepa 1-6 cell in 6-well plate
with 50 µM biotin in medium. After 24 hrs of expression, cell was washed twice in PBS
and lysed in BioID lysis buﬀer 1. Then equal volume of BioID lysis buﬀer 2 was added
and mixed. Clarified supernatant was collected and incubated with 100 µL Dyna-Beads
(MyOne Streptavidin C1 from Life Technologies) overnight. One the second day, beads
were collected and washed twice with BioID wash buﬀer 1 on a magnetic separator
(DynaMagTM–Spin Magnet). The washing was repeated once with BioID wash buﬀer
2, once with BioID wash buﬀer 3 and twice with BioID wash buﬀer 4 (all buﬀers used
in substrate trapping are listed in Table A.4). Finally, protein was eluted from beads
by BioID elution buﬀer. Protein sample was either submitted for western blot cross
validation or mass spectrometry identification, which is performed at DKFZ’s in-house
proteomics core facility.
4.3.5. Luciferase assay
All promoter reporters used in this project were cloned into pGL3 promoter from
Promega. Transfection of luciferase reporters into hepa 1-6 cell was titrated and op-
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timized for 96-well or 24-well plate. Cell was lysed in either 50 µL or 200 µL passive
lysis buﬀer from Promega’s Duo-luciferase reporter assay system, and renilla luciferase
was used as control.
4.3.6. Inducible shRNA stable cell line generation
Hepa 1-6 cell was transfected with piggBac transposase expression plasmid and shRNA
containing plasmid using Eﬀectene R⃝ transfection reagents from Qiagen. After 6 hour
post-transfection, cell was selected under 3 µg /mL puromycin until clones were formed
under microscope check. shRNA integrated cell was either submitted for continuous
selection for two weeks or picked as single clone for continuous selection for additional
two weeks. Generated stable cell line was submitted for 1 week puromycin selection
every month during culture.
4.3.7. FACS analysis of 2NBDG uptake
Stable cell line with inducible shRNA or empty hepa 1-6 cell was cultivated and induced
for 3–4 days and then starved in serum-free DMEM overnight. Then these cells were
sensitized in KRPH buﬀer (20 mM HEPES, 5 mM KH2PO4, 1 mMMgSO4, 1 mM CaCl2,
136 mM NaCl, 4.7 mM KCl, adjust pH to 7.4 (from pH 5.1 to 7.4)) for 1 hour and the
mixed with 2NBDG up to 100 µM, 20 min to allow glucose analog uptake. Uptake was
stopped by washing with PBS for 3 times and then digested with 0.25% trypsin for 3
min. Digestion was stopped by adding equal volume of FBS (fetal bovine serum from
PAA). All the cells were suspended and washed in PBS with 2% FBS for 3 times before
FACS measurement. 2NBDG intensity was recorded in the same channel for GFP on
BD’s FACSCantoTM II. FACS data was analyzed either in FlowJo or R.
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4.4. Virus production for mouse in vivo knock-down
4.4.1. shRNA packaging Adenovirus construction and production
4.4.1.1. Adenovirus with shRNA-NC/3 construction
The BLOCKiTTM Adenoviral RNAi System from Life Technologies was employed to
clone and package control shRNA or shRNA3 (targeting common region of all splicing
isoforms of PPP2R5C ) from ds oligos. Oligonucleotide sequences were designed using
Invitrogens online RNAi Design server [90]. Two complementary ssDNA oligos against
the target gene sequence were ordered from Sigma, and re-suspended as 200 µM in
water. Then oligo mixes with 1×annealing buﬀer was denatured at 98◦C and annealed
from 98◦C to 90◦C, then hold for 5 minutes, and annealed again from 90◦C to room
temperature. The annealed ds oligo products were checked by 4% agarose gel and
cloned into the pENTRTM/U6 vector according to the manufacturers instructions. The
sequence verified constructs were recombined with the pAd/BLOCK-iTTM DEST vector,
which contains the adenovirus serotype 5 DNA but not the E1 and E3 genes that are
required for viral replication. The viral vector containing the shRNA sequence was
linearized by restriction digest using the enzyme PacI and transfected into HEK239A
cells using Lipofectamine 2000 reagent according to the manufacturers instructions.
HEK293A cells express the viral E1 and E3 genes necessary for viral lysis, which allows
the virus to be propagated in culture medium. Viral plaques become visible from 6 to
10 days after transfection and cell monolayer started to form plaques. When ~70% of
cells were round and detaching, it was time to harvest them.
4.4.1.2. Adenovirus harvesting
HEK293A cells containing adenovirus were harvested from the medium after complete
detachment of all round infected cells. The medium was collected from up to 20×15
cm culture dishes and centrifuged at 2, 000 rpm, 4◦C for 10 min. The supernatant
was then discarded and the pellet was resuspended in 4 mL PBS-TOSH buﬀer inside
15 mL Falcon tube. The cell pellets in Falcon tube were frozen in liquid nitrogen and
subsequently thawed at room temperature on vortex for 3 times for maximal cell lysis
and adenovirus releasing. After 3 times lysis the cell suspension was centrifuged at 2,
000 rpm, 4◦C for 10 minutes. The clarified supernatant was then stored at -80◦C or
directly submitted for a CsCl gradient purification.
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4.4.1.3. Adenovirus purification by CsCl gradient
Virus lysates from Section 4.4.1.2 was filled with PBS-TOSH upto 20 mL final volume.
CsCl gradients were prepared in ultracentrifuge tubes (Beckmann Polyallomer 25mm×89
mm) and were weight-balanced after addition of each solution. At first, ~9 ml 4 M
CsCl was added, then ~9 ml of 2.2 M CsCl was added and finally the viral lysate was
carefully added on top in one liquid droplet by one fashion. In the end, there should
be 3 diﬀerent visible gradient layers. These gradients were centrifuged at 24, 000 rpm,
4◦C in ultracentrifuge XL-70 (Beckmann) with a SW28 swing bucket rotor for 2 hrs.
After ultracentrifugation a visible white band representing the concentrated adenovirus
fraction was formed between the 4 M and 2.2 M CsCl gradients. The band was collected
by inserting into the tube with 25G needle connected with 5 ml syringe. The collected
virus (~3 ml) fraction was then diluted with equal volume of saturated CsCl and changed
into a 12 mL ultracentrifuge tube (Beckmann Polyallomer 14mm×89 mm). ~2 ml of 4
M CsCl and 2.2 M CsCl were utilized again to form gradients. Then a centrifugation
at 35, 000 rpm, 4◦C was applied in an SW41 Ti swing bucket rotor for 3 hrs. The viral
fraction was visible again as a white band between the 4 M and 2.2 M CsCl gradients.
The fraction (~700 µL) was collected using a needle and 1 ml syringe. Finally, the viral
fractions were dialyzed (Spectra/Por R⃝ Biotech, MWCO 15,000, 10 mm diameter) in 1
L 1×PBS with 10% glycerol (v/v) for 2 times (1 and 24 hrs each) at 4◦C. After dialysis,
50–200 µL adenovirus in PBS were aliquoted and stored at -80◦C before use.
4.4.1.4. Adenovirus titration
Adenovirus titer was determined by the Tissue Culture Infectious Dose 50 (TCID50)
assay. For titer measurement, 104 HEK293A cells/well were cultivated in 100 µL DMEM
medium with 2% FCS (v/v), 1timesP/S and 1% NEAA in 96-well plate. In order to have
more accurate TCID50 calculation, technical duplicates of 96-well plate were required
for titer measurement. Cells were completely attached to the plate after 4 hours seeding.
During cell attachment, serial dilutions of the adenoviruses (1.65 ml for each dilution,
from 10−6 − 10−13) were prepared in the same medium as that for cultivation. 100 µL
of each virus dilution was added to ten wells and 100 µL of medium without virus was
added to the rest two well in the same row in 96-well plate as negative control wells.
The infected cells were cultivated for 10 days for continuous monitoring plaque formation
everyday. At day 10, the number of wells with at least one plaque was investigated under
microscope for each dilution, and the the titer was calculated with following formula:
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Ta = viruses per 100 µL = 101+(S−0.5)
S = the sum of all positive wells starting from
the 10−1 dilution, whereby 10 positive wells
correspond to the value 1.
T = viruses per 1 ml = 10× Ta
4.4.2. miRNA packaging Adeno-Associated Virus construction and
production
4.4.2.1. miRNA containing AAV construction
PPP2R5C -specific or non-targeting scramble control miRNA was cloned into Invitro-
gen’s adeno-associated virus system for long-term knockdown of PPP2R5C in vivo. The
Oligonucleotide sequences were designed using Invitrogens online RNAi Design server
[90], and listed in Table A.4. The oligos were then synthesized from Sigma, then an-
nealed and cloned into the pcDNA6.2-GW/EmGFP-miR vector. Later these oligos were
sub-cloned into pdsAAV-LP1-EGFPmut AAV vector [103] between the BglII and SalI
sites. The pdsAAV plasmids with miRNAs were co-transfected into HEK293T cells
for AAV production, together with the pDG∆VP helper plasmid [167] and a mutated
p5E18-VD2/8 expression vector [168] encoding AAV2 rep and a mutated AAV8 cap pro-
tein. For virus production, cells from 6×15 cm culture dish with 90% confluence were
scrapped and resuspended in 1100 ml DMEM medium (with 10% FCS, 1timesP/S).
1000 ml of the cell suspension was transferred to a 10×cell-stack chamber for first round
virus production. And the left 100 ml was transferred to a 1×cell stack chamber as
cell source for second round virus production in 10×cell-stack (could also used as con-
trol chamber for checking cell density). 2 days after plating, the cells in 10×cell-stack
chamber were reaching 90% confluent and co-transfected with the plasmids encoding
the viral genes using the PEI method in the amounts described below.
Plasmid amount in µg
AAV-miRNA expression vector 395
p5E18 VD2/8 helper plasmid 497
pDG∆VP helper plasmid 1353
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After 1 or 2 day transfection, cells were ready for harvesting and washed with 1×PBS
once. Then 10 or 100 mL trypsin was added to 1× or 10×cell-stack for 5 minute
digestion at 37◦C respectively. 40 ml or 350 mL full DMEM medium with serum was
added into for quenching trypsin digestion. And then the cells were transferred into
a 50 mL falcon tube, or a 500 mL conical tube. For cells in 50 mL falcon tube, they
were repopulated in used 10×cell-stack chamber for the second round cell transfection
and harvesting. The cells in 500 mL conical tube were spun down at 2000 rpm for 10
min. The supernatant was discarded and the cell pellets were resuspended in 8 mL lysis
buﬀer (150 mM NaCl and 50 mM Tris-HCL, pH 8.5) and transferred in 15 Falcon tube,
frozen in liquid nitrogen and stored at -80◦C.
4.4.2.2. AAV crude lysate preparation
AAV lysates from step above were thawed at 37◦C until half frozen and half suspension
mixture formed. Then the votexing was employed to have complete thawing. The virus
containing supernatant was collected by 10 minute centrifugation at 3500×g. The cell
pellets were remixed in 4 mL lysis buﬀer and then snap-frozen in liquid nitrogen. The
freezing-and-thaw cycle was repeated for 3 times to have maximal cell lysis. The final
thawing step was employing 1 minute sonication before centrifugation for better cell
lysis. Finally, suspensions from all steps were pooled and digested with benzonase (50
U/ml) for 30 min at 37◦C to remove any transfected plasmid and naked DNA. This
virus lysate was then centrifuged at 4◦C and 3,500 g for 10 min to remove the pellet and
then stored at -80◦C until further use.
4.4.2.3. AAV iodixanol gradient purification
AAV crude lysates were further purified by two-step iodixanol gradient. 4 gradients with
diﬀerent concentration were prepared as in table as follow (quantity for 15 gradients):
Iodixanol Gradient %15 %25 %40 %60
OptiPrep 17.5 mL 31.2 mL 40 mL 60 mL
PBS-MK-NaCl 52.5 mL
PBS-MK 43.8 mL 20 mL
0.5% Phenol Red 187.5µL 150µL
Total 70 mL 75 mL 60 mL 60 mL
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Lysates were transferred into centrifugation tube via Pasteur pipette. 4 diﬀerent gradi-
ents were sequentially under-layered through Pasteur pipette. Then centrifugation tube
was sealed and ~1 mL air bubble was left inside. Gradients were centrifuged at 50, 000
rpm, 2.5 hours and 10◦C in 50.2Ti rotor. Purified virus fraction was taken out by in-
serting 20G needle into 60% layer and collecting roughly 3.5 mL 40% gradient fraction.
In the second step gradient purification, only 25%, 40% and 60% gradient were used for
purification. Other procedures were the same as in step 1. After two round gradient
purification, virus fraction was dialyzed against PBS overnight with 3 changes of PBS.
Then virus fraction was transferred into Vivaspin-6 tube and spun and resuspended at
2000–4000 rpm for 3–5 min until the final volume is 1000-1500 µL. Finally, virus elute
was aliquoted and stored at -80◦C until further use.
4.4.2.4. AAV titration
5 µL virus solution was mixed with 5 µL H2O and 10 µL NaOH and then incubated at
55◦C to allow complete release of the viral genome. Then this solution was neutralized
by adding 10 µL HCl and diluted by adding 970 µL H2O. Finally, 5 µL was submitted
to qPCR analysis with probe for GFP sequence in AAV genome. For quantification,
the standards were prepared by diluting AAV genome plasmid from 1013 copies/mL
step-wise into 102.
4.5. Metabolite measurement in celluar and tissue
samples
4.5.1. Glucose consumption in Hepa 1-6 and primary hepatocytes
Hepa 1-6 cells or mouse primary hepatocytes were cultured as condition described before.
At day 0, adenovirus packaged with scramble shRNA or shRNA3 (targets all PPP2R5C
transcripts) were incubated with cell for 3-day infection experiment at MOI of 10, 100,
or 200. After 24 hours, media with virus was washed away by 3 time washing with
fresh medium. Cell media was replaced everyday, and media for last 24 hour infection
was collected for glucose consumption assay. Glucose concentrations from 2.5 µL of
these media or control media (fresh media) were measured by Glucose HK assay kit
from Sigma, and relative glucose consumption was calculated by subtracting glucose




The same media collected for glucose consumption assay was also used for lactate pro-
duction assay. 2 µL of each medium was submitted for lactate concentration measure-
ment by using a lactate kit from Roche (D-Lactic acid/L-Lactic acid, Cat. No. 11 112
821 035). And lactate production rate in 24 hour was calculated from relative lactate
production compared with fresh medium.
4.5.3. Free fatty acid measurement
Sample for free fatty acid measurement was prepared diﬀerently among various samples.
For media sample, all the lipid content was enriched by Methanol-Chloroform method
[102]. 2 volume of methanol:chloroform mix (2:1 in volume ratio) was mixed well with 1
volume of media (if media does not contain Triton X-100, add 10 µL chloroform:Triton
X-100 mix (1:1 in volume ratio)), and then was shaken at room temperature at 250 rpm
to allow complete extraction of lipid fraction. Then these solutions were spun down at
maximal speed on a desktop centrifuge for 5 min, room temperature to separate the
water:methanol phase and the chloroform phase. Then lipid fraction was collected from
the lower chloroform phase, and mixed with 0.4 volume of 0.9% NaCl for cleaning. Final
spin on this solution will separate the chloroform phase with the water phase on the
top. Final lipid fraction was collected and dried in a speed-vac for at least 3 hours
until there was a Triton X-100 pellet formed. Finally, pellet was dissolved in water and
submitted to fatty acid measurement using the kit from Cayman Chemical (Free Fatty
Acid Fluorometric Assay Kit) under the instruction manual from the manufacturer.
For cellular samples lysed by IP lysis buﬀer (150 mM NaCl, Tris pH 7.5, 1% Triton
X-100), they could be submitted to fatty acid measurement directly if the fatty acid
concentration was within the range of standard curve. If not, then these samples must
be enriched as before. For tissue sample such as mouse liver, The sample is needed to be
pulverized and weighted before suspending in methanol:chloroform mix (2:1 in volume
ratio). For 100 mg liver tissue powder, 1.5 mL mix was added and shaken at room
temperature for 20 min. The following procedure for collecting lipid fraction was similar
with these for media samples.
For serum samples, 2 µL of serum was subjected to fatty acid measurement by NEFA
HR kit from Wako Chemicals. 2 µL serum sample or diﬀerent amount of standard (1
mM/L oleic acid, 0.5 - 5 µL) was first mixed with 200 µL R1 reagent, and incubated at
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37 ◦C in Tecan microplate reader Infinite M200 for 2 min to read the absorbance 546
nm as blank. Then 100 µL R2 reagent was added at 3 min, and absorbance at 7.5 min
was recorded as final reading. Serum NEFA was calculated from back calculation from
the standard curve.
4.5.4. Triglyceride measurement
Sample preparation procedure for triglyceride measurement were the same as the ones
for free fatty acid measurement. After sample was lysed or enriched, normally 2–20
µL sample was mixed and incubated with 5 µL lipase solution (10 mg/mL) at 37 ◦C
overnight to release the glycerol from triglyceride. Then free glycerol content was mea-
sured by free glycerol assay kit from Sigma. Triglyceride concentration was calculated
and normalized to the total protein content in the very same sample.
4.5.5. Cholesterol measurement
Cholesterol was measured from the same sample for triglyceride or free fatty acid mea-
surement. For serum sample, 2–4 µL serum was directly submitted for measurement.
All cholesterol measurements were done using cholesterol (liquid) assay kit from Randox
Laboratories (Cat. No. CH201) according to the standard protocol shipped with the
kit. Cholesterol concentration was calculated from control with known concentration.
4.5.6. Glycogen content determination
For measuring glycogen from cellular lysate, such as Hepa 1-6 in 6 well plate, cell was first
lysed in 500 µL IP buﬀer and 30 µL of the lysate was mixed with 1 µL amyloglucosidase
solution (14 U/µL) overnight at 37 ◦C. For tissue sample such as mouse liver, ~50 mg
liver was weighted (recording the weight for normalization) and homogenized in 1 mL
30% KOH with Qiagen tissue lyser. Then the homogenate was incubated at 95 ◦C
for 30 min and clarified by maximal centrifugation in a desktop centrifuge for 10 min.
Supernatant was collected and mixed with 1.5 mL 95% ethanol to precipitate glycogen.
Glycogen pellet was collected by spinning at 3000×g for 20 min and then washed with
95% ethanol, dried at room temperature. Then the pellet was dissolved in 500 µL water
(in case there was solubility issue, heat to 37 ◦C for 30 min). 5 µL glycogen solution was
digested using 295 µL amyloglucosidase solution (30 U/mL in 0.2 M NaAc pH 4.8) and
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then neutralized with 6 µL 30% KOH. 10 µL of the digested glycogen was submitted to
glucose measurement using the same kit for glucose consumption assay.
4.5.7. Ketone body measurement
Total ketone body and 3-hydroxybutyrate were measured using Autokit total ketone
bodies and 3-HB kit from Wako Diagnostics. 2 µL of each serum was taken for mea-
surement. And procedures were the same according to the manufacturer’s instruction.
All the reading was done in 96 transparent well and recorded on Tecan infinite M200 at
405 nm.
4.5.8. ATP measurement
Intracellular ATP level was measured using ATPliteTM from Perkin Elmer. 50 µL of
Hepa 1-6 lysate (lysis in 500 µL IP buﬀer for 107 cell) was mixed with equal volume of
reagent and read for luminescence intensity within 20 min on Tecan infinite M200.
4.5.9. Intraperitoneal glucose tolerance test (IPGTT)
Mice were starved for 6 hours before injecting 2g glucose/kg body weight intraperi-
toneally. Blood glucose was collected from cutting at tail and measured right after
injection. Then 50 µL blood was also collected from the same cutting point for mea-
suring insulin in the serum. At time point 20, 60, 90, 120, 150 min, blood glucose
concentration was measured and extra 50 µL blood was collected for later insulin mea-
surement at time point of 20 and 60 minute. Blood was incubated at 4 ◦C to allow
separation of serum and serum was collected by spinning at 5000 rpm for 30 min. All
blood glucose measurement was done by using a glucose measurement kit from One
Touch Glucose Monitor (Lifescan).
4.5.10. Serum insulin measurement
Mouse insulin in the serum was performed using mouse insulin ELISA kit from Alpco.
5 µL serum was used for mouse serum from random fed mice. For GTT assay or
serum from fasting mouse and refed mice, 25 µL was taken for measurement. Insulin
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concentration was calculated from 5 parameter logistic regression of standard curve data
(0.188–6.9 ng/mL) in R package drc. All the reading was done in 96 transparent well
and recorded on Tecan infinite M200 at 450 nm.
4.5.11. Serum lipoprotein particle analysis
200 µL of pooled serum from 5 or 6 mice (40 or 33.3 µL for each mouse) and 100 µL 1×
PBS were mixed and spun for 2 min at 10, 000×g, 4 ◦C to clarify. And then the 300 µL
mixed solution was subjected to FPLC separation on SuperoseTM 6 10/300 GL column
(GE Healthcare) in 25 mL PBS at flow rate of 0.5 mL/min. Lipoprotein particle peaks
were monitored with UV 280nm. VLDL, LDL and HDL eluted at 7-8 mL, 12-14 mL
and 16-18 mL respectively. 0.5 mL/Fraction was used to collect each fraction, and then
160 and 40 µL from each fraction was used to determine the triglyceride and cholesterol
content per fraction respectively.
4.5.12. Serum ALT measurement
Serum ALT (Alanine Aminotransferase) activity was measured by the Infinity ALT/GPT
Reagent (Thermo Scientific). 5 µL serum or H2O was added into 100 µL ALT reagent
on 96-well transparent plate (SARSTEDT). Then the microplate was incubated at 37
◦C and recorded UV 355 nm on the microplate reader (Infinite R⃝ M200, Tecan) at time
of 1 min and 9 min. Then the ALT activity was calculated as following equation.
ALT = ∆A1min−9min8 × 11029.4(U/L)
4.5.13. Seahorse analysis of glycolysis in Hepa 1-6
Pre-split hepa 1-6 cell was washed once with 180 µL assay medium (DMEM (Sigma
D5030) with 143 mM NaCl, 2 mM L-Glutamine, pH 7.35±0.05. Adjust pH at day of
assay.) and incubated with 175 µL assay medium at 37 ◦C for 1 hour in 96-well plate
from XF96 glycolysis stress kit (Seahorse Bioscience). Then 25 µL of each glucose (10
mM in assay medium), oligomycin (2.5 or 1 µM in assay medium) and 2-deoxyglucose
(100 mM in assay medium) was injected into plate reservoir and then glycolysis rate
was recorded on XF96e Extracellular Flux Analyzer from Seahorse Bioscience. All the
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data collection and analysis was done in built-in software for XF96. Data normalization
was done by counting average nuclei number in Cell Profiler from DAPI staining and
normalization to average nuclei count.
4.6. Biochemical methods
4.6.1. Protein expression in bacteria
Variant 3 of PPP2R5C was sub-cloned into 6 × His tag purification system. Expression
plasmid was transformed into 4 diﬀerent bacteria strains by electroporation in Bio-Rad’s
Gene Pulser XcellTM Electroporation Systems, include Lucigen, Rosetta, RP and RIL.
Strain with the highest induction under IPTG was selected for protein production. 1 L
bacteria culture was shaken at 37 ◦C until O.D. 600 exceed 2 and then IPTG induction
was done at 18 ◦C overnight at 1 mM. Protein purification on 6 × His tag resin from
Qiagen were performed according to suppliers’ instruction.
4.6.2. Antibody production and purification
Purified PPP2R5C was dialyzed in PBS with 5% glycerol overnight and then concen-
trated by Vivaspin 2 with 3000 MWCO until protein concentration reached 1 mg/mL.
Antigen was mixed with equal volume of Freund’s adjuvant complete and injected 250
µL per guinea pig at each 3–4 weeks. Around 50 µL blood was collected at 1 week
after injection. Serum was separated and tested for specificity for antigen at 1:200–1000
dilution in western blot.
4.6.3. SDS-PAGE and western blot
All protein samples, including lysates from cell, tissue or serum fractions, were de-
natured in 1×Laemmli buﬀer (60 mM Tris-Cl pH 6.8, 2% SDS, 10% glycerol, 5% β-
mercaptoethanol, 0.01% bromophenol blue) and boiled at 95 ◦C for 5 min. SDS-PAGE
gels were prepared at diﬀerent percentage using Tris-Glycine gel system. Gel was run-
ning at 20 mA/gel with 200 V limit for 1 hour. And then gel was washed in transfer
buﬀer (25 mM Tris, 192 mM Glycine, 20% Methanol) shortly before assembled into wet
transfer sandwich with Whatman paper and 0.22 µM nitrocellulose membrane from GE
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Healthcare. Protein was transferred onto nitrocellulose membrane at 100 V for 1 hour
at 4 ◦C. Afterwards, protein was visualized by Ponceau S staining (0.2% in 3% TCA)
and blocked with 5% BSA or skim milk (Sigma) for 1 hour. Then the membrane was
washed with PBST (1×PBS, 0.1%Tween-20) for 3 times, 10 min each. Incubation with
primary antibody was done at 4 ◦C overnight. Then the membrane was washed for 3
times, 10 min each. Secondary antibody was diluted in 5% skim milk and incubated
with membrane at room temperature for 1 hour. Finally, the membrane was washed 3
times, 10 min each, and developed with ECL reagents from Thermo Scientific.
4.6.4. Phos-tag R analysis of phosphorylated proteins
For protein separation using Phos-tag R⃝ analysis, all protein lysate samples were cleaned
by Methanol-Chloroform precipitation [169] and re-solubilized in 1×Lamelli buﬀer. 25
µM Phos-tag R⃝ was used to incorporate with 8% SDS-PAGE gel. Other procedures were
performed under the instruction manual of Phos-tag R⃝.
4.6.5. Immunoprecipitation
Total protein lysates were prepared by lysing cell in IP buﬀer (50 mM Tris, pH 7.5, 150
mM NaCl, 1% Triton X-100) for 15 minutes on ice and then collecting supernatant after
centrifugation of 14, 000 rpm at 4 ◦C for 15 minutes. Then lysates were incubated with
1 µL antibody (0.5 mg/ml) for 3 hours at 4 ◦C, and 30 µL Protein A Agarose slurry
(Roche) for additional 0.5 hour. Agarose beads were washed in cold IP buﬀer for 3 times
with centrifugation at 2000 rpm, 4 ◦C for 1 minute to discard the supernatant. Final
IP fraction was eluted in 2×Lamelli buﬀer and boiled at 95 ◦C for 5 minutes.
4.7. Animal experiments
8–10 week C57BL/6J male mice was purchased from Charles River Laboratories and
maintained with unlimited water and normal chow food at 12 hour light–dark cycle.
After 1 week adaptation, mice were tail-injected 100 µL control or knockdown AAV
diluted in 1×PBS. After 7 week infection, mice were subjected to ad libitum feeding, 16
hour fasting or 16 hours fasting + 6 hour refeeding.
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4.8. Data analysis and plotting
Data for mouse serum and liver metabolites were imported and analyzed in R [170].
For liver TG in random fed mice, ANCOVA model was used to estimate the eﬀect
of PPP2R5C knockdown by AAV. Two variables liver NEFA and AAV (miRNC and
miR12) were used as covariates to predict the liver TG. In GTT measurement, repeated
measures ANOVA model was used to evaluated the eﬀect of PPP2R5C knockdown on
glucose clearance rate. For other metabolite measurements, pairwise.t.test function in R
was employed to perform multiple comparisons between 3 diﬀerent treatments (Random
Fed, Fasting, Refed) and 2 diﬀerent AAVs (miRNC, miR12). p-value form multiple
testing was controlled by Benjamini & Hochberg method [134]. All the plotting was
done either using R core graphics or ggplot2 [171].
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A.1. Chemicals and kits
Table A.1.: Chemicals and kits used in all experiments
Chemical Company Ordering No.
N-Z-Amine A Sigma C0626
Ammonium persulfate Sigma A9164




Cobal chlorid Sigma 60818








Guanidine hydrochloride Sigma G4505
HEPES AppliChem A37240500
Hematoxylin Solution Sigma MHS16
Imidazole AppliChem A10730100
Kanamycin sulfate AppliChem A14930025
Lithium chloride Sigma 62478











Nile Red MP 180085405
Nonidet R⃝ P40 AppliChem A16940250
Orange G Fluka 75380
Oil Red O solution Sigma O1516
Oil Red O powder MP 155984
pH-Puﬀerloesung pH 10 Roth H910.1
pH-Puﬀerloesung pH 7 Roth H908.1
pH-Puﬀerloesung pH 4 Roth H906.1
Polyethylene glycerol Sigma P3640
Pierce 660nm Protein As-
say
Thermo 22660
Ponceau S solution SERVA 3342701
Potassium chloride Roth 67811











Propylene Glycerol MP 151957
Polyethylenimine Polysciences Inc 24765
Sodium hydroxide pellets Riedel 30620










Sodium carbonate Roth A1351
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Chemical Company Ordering No.
SDS ultrapure AppliChem A11121000
Sodium bisulfite Sigma 243973
Sodium deoxycholate Sigma D6750
Sodium fluorid AppliChem A39040100
Sodium azid AppliChem A14300100
Tween-20 AppliChem A13891000
Trizma Base (Tris) Sigma T1503
Thiourea Sigma T8656








Yeast Extract Fluka 70161
LB Broth Sigma L3022




L-(+)-Arabinose, 98% Sigma A91906
L-Glutathione reduced Sigma G6013
Glutathione Sepharose Amersham 17075601










BSA Albumin Fraction V AppliChem A1391










Acrylamide 30% 4k 37.5:1 AppliChem A16721000
PhosSTOP Roche 04906837001
















Streptavidin HRP invitrogen T20932




eﬀectene reagent kit Quiagen 301427
Opti-MEM reduced Gibco 31985-062
Pen-Strep 100x PAA P11-010
L-Glutamine solution Gibco 25030-024
Trypsin-EDTA solution Gibco 25200-056
MEM non essential Amino
Acids
Sigma M7145
FBS Gold PAA A11-151
DMEM (4.5g/l Gluc; + L-
Glut)
Gibco 41965-039











Chemical Company Ordering No.
Cholesterol (liquid) assay Randox, Crumlin, UK CH201
Total Ketone Bodies Wako, Neuss 415-73301&411-
73401
HR Series NEFA-HR Wako, Neuss 999-34691&991-
34891
A.2. Antibodies
Table A.2.: Antibodies used in all experiments
Antibody Suppliers
anti myc-Tag (71D10) Cell Signaling 2278
anti Phospho-p70 S6K (Thr389) Cell signalling 9205L
anti HA tag (clone 3F10) Roche 11 867 423 001
anti AKT (total protein) Cell Signaling 9272
anti FLAG tag M2 Sigma F 1804
anti phospho-ERK1/2(p44/42) Cell Signaling 4370
anti AMPK b1 Cell signaling 4148
anti AMPK b2 Cell signaling 4178
S6 ribosomal protein (54D2) Cell Signaling 2317
anti phospho-S6 ribosomal Protein (Ser235/236) Cell signaling 4857
anti p70 S6 Kinase Cell Signaling 9202
anti human PP2A catalytic BD 610555
anti p-AKT(Thr308) Cell Signaling 2965S
anti p-AKT(Ser473) Cell Signaling 9271
anti Ribosomal Protein L26 Cell Signaling 2065
anti YAP Cell Signaling 4912
anti p-GSK3-beta (Ser9) Cell Signalling 5558
anti p-AMPK a (T172) (40H9) Cell signaling 2535S
anti GFP Teleman’s production
anti AMPKa Cell signaling 2532S
anti HSP90 (C45G5) Cell signaling 4877
anti p-Acetyl-CoA Carboxylase (Ser79) Cell Signaliing 3661
anti TSC1 Cell Signaling 4906




anti SREBP-1 BD Biosciences (557036)
anti HIF1a Cell Signaling 3716
anti p-Stat3 (Ser727) Cell Signalling 9134
anti STAT3 Cell Signaliing 9139
anti HIF1a GeneTex
anti GAPDH Cell Signaling 2118
anti CHD4 Cell signaling 4245
anti VDUP1 (B-2) Santa Cruz sc-166234
anti p-TBC1D1 (Ser660) Cell signaling 6928
anti p-TBC1D1 (Ser700) Cell signaling 6929
anti p-AMPK b1 S108 Cell signaling 4181
anti SREBP-2 (H-164) Santa Cruz sc-5603
anti Glut1 (H-43) Santa Cruz sc-7903
anti TBC1D1 (V796) Cell signaling 4629S
anti Acetyl-CoA Carboxylase (C83B10) Cell Signaling 3676
A.3. Instruments
Table A.3.: Instruments used in all experiment
Instruments Suppliers
Peltier Thermal Cycler DNAEngine Bio-Rad, Munich
Step One Plus Real-Time PCR System Applied Biosystems, USA (Now part of
Thermo Scientific)
MicroPulser Bio-Rad, Munich
FlexCycler Analytik jena, Germany
Uvsolo TS Imaging system Biometra, Gottingen
SPECTROstar Omega BMG LABTECH GmbH, Ortenberg
TriStar2 multimode reader Berthold Technolog, Bad Wildbad
Avanti J-25 Beckmann, Munich
Duomax 1030 horizontal shaker Heidolph, Kehlheim
Analytic Scales Satorius, Gottingen
CERTOMAT BS-T Satorius, Gottingen
Wet Transfer Blotting Bio-Rad, Munich




Centrifuge 5810R Eppendorf, Hamburg
Centrifuge 5430 Eppendorf, Hamburg
Electrophoresis system Bio-Rad, Munich
Film cassette GE Healthcare, Salt Lake City, USA
Film Developer Sanyo, Munich
AKTA purifier 10 GE Healthcare, Salt Lake City, USA
Odyssey R⃝ Fc LI-COR Biotechnology GmbH, Bad Hom-
burg
Infinite M200 Tecan Group Ltd.,Switzerland
One Touch Glucose monitor Lifescan, Neckargemund
pH-meter Satorius, Gottingen
Nano-Drop 1000 Thermo Scientific, USA
XF96 analyser Seahorse Bioscience, Massachusetts,USA
Tissue lyzer Qiagen, Hilden
FACS Canto II BD Biosciences, San Jose, USA
Benchtop Heater PCH-1 Grant Instruments, UK
Electrophoresis Power Supply VWR international, Darmstadt
DNA gel electrophoresis chamber Peqlab Biotechnology, Erlangen
Magnetic mixer MR 2002 Heidolph, Kehlheim
Compatible Control CC-1 Peter Huber Kaltemaschinenbau GmbH, Of-
fenburg
A.4. Solutions and buﬀers
Table A.4.: Buﬀers used in all experiments
Buﬀers Recipes
HANKS Buﬀer 2L containing 16.0 g NaCl, 7.1 g HEPES, 800 mg
KCl, 120 mg Na2HPO4, 120 mg KH2PO4, pH 7.4
HANKS I 400 mL HANKS buﬀer, 152 mg EGTA (1 mM final),
4 mL 10% Glucose (0.1% final)
HANKS II 400 mL HANKS buﬀer, 100 mg Collagenase CLS II
(0.3 mg/ml final), 389 mg CaCl2•2H2O (10 mM fi-




Adehesion Medium 10% FCS, 1% P/S, 2mM Glutamine, 0.01 mg/mL In-
sulin, 100 nM Dexamethsone in Williams E Medium
PBS-Tosh 30.8 mM NaCl, 120.7 mM KCl, 8.1 mM Na2HPO4,
1.46 mM KH2PO4, 10 mM MgCl2, pH 7.2
IP lysis and washing buﬀer 150 mM NaCl, 50 mM Tris, 1% Triton X-100, pH 7.4
BioID lysis buﬀer 1 50 mM Tris, pH 7.4, 500 mM NaCl, 0.4% SDS, 5
mM EDTA, 1 mM DTT, and 1×Complete protease
inhibitor from Roche
BioID lysis buﬀer 2 50 mM Tris, pH 7.4
BioID wash buﬀer 1 2% SDS
BioID wash buﬀer 2 0.1% deoxycholate, 1% Triton X-100, 500 mM NaCl,
1 mM EDTA, and 50 mM Hepes, pH 7.5
BioID wash buﬀer 3 250 mM LiCl, 0.5% NP-40, 0.5% deoxycholate, 1 mM
EDTA, and 10 mM Tris, pH 8.1
BioID wash buﬀer 4 50 mM Tris, pH 7.4, and 50 mM NaCl
BioID elution buﬀer Biotin saturated 1×Laemmli sample buﬀer
A.5. Primer list for quantitative RT-PCR
Table A.5.: Primer list for quantitative RT-PCR
Oligo No. Primer Sequence Name
OAT1632 CGGTCGCAATGGAGACA Foward primer for mPPP2R5C
variant 1+4
OAT1633 GGGGACGATCCTTCTTCA Reverse primer for mPPP2R5C
variant 1+4
OAT1634 GCGAATCCCCAGGCACA Foward primer for mPPP2R5C
variant 2
OAT1635 GTGTGGGGGTCCTGAGG Reverse primer for mPPP2R5C
variant 2
OAT1636 GCACTCAGCAGTTCAAAGC Foward primer for mPPP2R5C
variant 3




Oligo No. Primer Sequence Name
OAT1638 CGTCGTCCCTGTGAAGAA Foward primer for mPPP2R5C
variant 4
OAT1639 GATCCGCAGGAGGAACAT Reverse primer for mPPP2R5C
variant 4
OYC175 AGTTTGTATTGCAGCTTCTA Foward primer for mPPP2R5C
OYC176 TCCAGTAACTCCGCTATG Reverse primer for mPPP2R5C
OYC124 AGGAGTATGGGCTTCATTGGGCA Foward primer for mAcly
OYC125 TCCCAGGGGTGACGATACAGCC Reverse primer for mAcly
OYC185 CCTGTGCTACCTTCTCTCTA Foward primer for mGPAT
OYC186 CTTCCTGGTCATCTTGCTCT Reverse primer for mGPAT
OYC197 CACACATCACTTAGCCAAC Foward primer for mHMGCS1
OYC198 GTCCTTCTGTGTTTTTCATC Reverse primer for mHMGCS1
OYC199 ATCTTCTTCCCTATTGCACT Foward primer for mLDLR
OYC200 TGGGTTGTCAAAGTTTATGC Reverse primer for mLDLR
OYC209 AGAAAGGTGGCAGGAGATCG Foward primer for mDGAT2
OYC210 GTCAGCAGGTTGTGTGTCTT Reverse primer for mDGAT2
OYC213 ATGACCAGACTTCCTCCAAC Foward primer for mSlc25a1
OYC214 GTATGTTCCCTTTAGCCCTT Reverse primer for mSlc25a1
OYC233 AGTTCCATTGACAAGGCCAT Foward primer for mSREBP1
OYC234 TACCGTGAGCTACCTGGACT Reverse primer for mSREBP1
OYC395 CCATTTCCACCATGATTAAGGGTCT Foward primer for mLDHa
OYC396 CGAGATTCCATTTTGTCCCAGGATA Reverse primer for mLDHa
OYC397 CAGATCTCTCAGCCCGCCAA Foward primer for mNDRG1
OYC398 GGCGAGTCATGCTGGCAGAA Reverse primer for mNDRG1
OYC399 ACAAGCTTCATCCTCACTTTGCC Foward primer for mHK2
OYC400 GGAAGGACACGTCACATTTCGGA Reverse primer for mHK2
OYC110 ATGGATGTTGGCAAGGCCCGA Foward primer for mPKM2
OYC111 AGGCACTACACGCATGGTGTTGG Reverse primer for mPKM2
A.6. shRNA/miRNA target sequences
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Table A.7.: List of software used
Software Provider
Image J NIH
R R core team
Oﬃce Suite Microsoft
Photoshop Adobe
ApE M. Wayne Davis





B.1. Enriched TFs in mouse cell lines upon PPP2R5C
KD
Table B.1.: Activated TFs in mouse primary hepatocytes and Hepa 1-6.





















B.2. Enriched TFs in mouse liver upon PPP2R5C KD
B.2.1. Enriched TFs in mouse liver during fasting
Table B.2.: Activated TFs in mouse liver upon PPP2R5C KD during fasting.
































B.2.2. Enriched TFs in mouse liver during ad libitum feeding
Table B.3.: Activated TFs in mouse liver upon PPP2R5C KD during random fed.
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AAV Adeno-Associated Virus. 40–42, 75, 96–98, 104, 105
ACLY ATP-citrate lyase. 66
AKT V-Akt Murine Thymoma Viral Oncogene Homolog, or Protein Kinase B. 14
ALT Alanine Aminotransferase, marker for liver injury. 41
AMPK 5′-AMP-Activated Protein Kinase. 7, 59, 60
ANCOVA Analysis of covariance. 48, 49
ANOVA Analysis of Variance. 20, 22–24, 45, 46, 70
APC Adenomatous Polyposis Coli. 15
ATP Adenosine triphosphate. 37, 60
AV Adenovirus. 75
BioID proximity-dependent biotin identification. 92
BirA Bifunctional ligase/repressor BirA. 59
BSA Bovine Serum Albumin. 104
CAK CDK-activating kinase. 16
CaMK-II Calcium/Calmodulin-Dependent Protein Kinase II. 7
cDNA Complementary DNA. 85, 87, 89, 90
CK-I Casein Kinase 1. 7
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CK-II Casein Kinase 2. 7
DAPI 4′,6-diamidino-2-phenylindole. 16
DGAT2 Diacylglycerol O-Acyltransferase 2. 66
DMEM Dulbecco’s Modified Eagle’s Medium. 91, 93, 95, 102
DNA Deoxyribonucleic acid. 84–87, 94
dNTP Deoxyribonucleotide. 84–86, 89
ELISA Enzyme-linked immunosorbent assay. 101
FACS Fluorescence-activated cell sorting. 33
FCS Fetal Calf Serum. 91, 95, 113
FPLC Fast protein liquid chromatography. 53, 102
gDNA Genomic DNA. 85, 87
GPAT1 Glycerol-3-Phosphate Acyltransferase 1, Mitochondrial. 66
GSK-3 glycogen synthase kinase 3b. 7
GST Glutatione S-transferase. 18
GTT Glucose tolerance test. 43, 47, 101, 105
HDL High-density lipoproteins. 8, 53, 102
HIF1a Hypoxia Inducible Factor 1, Alpha Subunit. 59, 61, 62, 65, 66
IDL Intermediate-density lipoproteins. 8, 53
IkBa Nuclear Factor Of k Light Polypeptide Gene Enhancer In B-Cells Inhibitor, Al-
pha. 18
IKK inhibitor Of Kappa Light Polypeptide Gene Enhancer In B-Cells Kinase, upstream




LDL Low-density lipoproteins. 8, 53, 102
miRNA microRNA. 26, 27, 40, 41, 88, 96
MOI Multiplicity of Infection. 31, 32
mTOR Mechanistic Target Of Rapamycin (Serine/Threonine Kinase). 14, 37
NEAA Non-essential amino acid. 91, 95
NEFA Non esterified fatty acid. 49, 52, 99, 100, 105
NF-kB Nuclear Factor Of k Light Polypeptide Gene Enhancer In B-Cells. 18, 25, 30,
75
NHGU Net Hepatic Glucose Uptake, µmol/kg/min. 5
P/S Penicillin-Streptomycin (10,000 U/mL). 95, 96, 113
PCR Polymerase chain reaction. 84, 86, 90
PEI Polyethylenimine. 96
PKA Protein Kinase A, cAMP-Dependent. 7
PKC Protein Kinase C. 7
PP2A Protein Phosphatase 2A. 12, 17, 58–60
PPP2R5C Protein Phosphatase 2, Regulatory Subunit B′, Gamma. 21, 23, 24, 26, 27,
29–31, 33–37, 39–41, 43, 47, 48, 52, 54, 56, 58–60, 62, 64, 65
qPCR Quantitative Real-Time PCR. ii, iii, 90, 98
S6K1 Ribosomal Protein S6 Kinase, 70kDa, Polypeptide 1. 17, 59
shRNA Short hairpin RNA. 26, 29, 33–36, 87, 88, 90, 93, 94, 98
SLC25A1 Solute Carrier Family 25 (Mitochondrial Citrate Transporter), Member 1.
66




TAP Tandem Aﬃnity Purification. 18
TCR T Cell Receptor. 18
VLDL Very-low-density lipoproteins. 5, 8, 53, 54, 56, 71, 75, 102
WD40 WD or beta-transducin repeats are short ~40 amino acid motifs with terminal
Trp-Asp (W-D) dipeptide. 13
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